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1. INTRODUCTION 
1.1. Epidemiology of Malaria  
Malaria is a parasitic disease caused by an infective bite of female Anopheles 
mosquitoes that transmits Plasmodium species. In sub−Saharan Africa and tropical 
countries, it is a leading cause of febrile illness and mortality, particularly in children 
below five years (WHO, 2018). From years 2005 until 2015, the global malaria burden 
has reduced considerably, as a result of effective control strategies by governments. 
In the last few years, however, this trend has stagnated in few countries, and an 
increased burden in certain countries are reported. The current estimates document 
approximately 220 million cases, with reported 400,000 malaria deaths globally (WHO, 
2018).  
 
In Kenya, 70% of the population (~35 million people) is at risk of malaria. The national 
malaria burden is about eight million with ~16,000 mortalities per year, making malaria 
the second leading cause of death after pneumonia (KNBS, 2017, Macharia et al., 
2018). Most of the cases are documented from western regions especially in the Lake 
Victoria basin and from Coastal Kenya. The climatic conditions in these regions serve 
as hotspots for malaria transmission (Figure 1). Apart from Nairobi and highlands of 
central Kenya, other regions experience epidemics (highlands of western Kenya) or 
seasonal transmission (northern and central Kenya) (NMCP et al., 2016). With these 
spatial differences in malaria transmission, control strategies are therefore adapted to 
meet the needs of a given locality (NMCP et al., 2016).  
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Figure 1: Map of Kenya showing P. falciparum prevalence (PfPR2–10). Adopted and 
modified from (Macharia et al., 2018) 
 
Three of five Plasmodium species known to infect human beings are present in Kenya, 
namely Plasmodium falciparum, P. ovale and P. malariae. Among them P. falciparum 
is the predominant and virulent species. It accounts for 98% of all malaria parasite 
infections in Kenya. The other species, P. ovale and P. malariae, occur at low 
prevalence. Even though P. vivax is not present in Kenya, it is found in few East African 
countries such as Ethiopia and Sudan (Howes et al., 2015). Other regions where P. 
vivax occurs include, South-East Asia, South America and the Western Pacific region 
(WHO, 2018, Howes et al., 2015, Howes et al., 2016). The P. knowlesi malaria is 
confined to forested areas of South−East Asia (Millar and Cox-Singh, 2015). 
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1.2. Plasmodium life cycle 
The life cycle of Plasmodium occurs partly in humans, intermediate host, and in the 
female Anopheles mosquitoes as definitive host (Figure 2). It is initiated by an infected 
mosquito bite. During a blood meal, sporozoites (infective stage of Plasmodium) are 
released from the mosquito salivary glands into the skin and/or blood capillaries 
(Cockburn and Seder, 2018). The sporozoites sequentially migrate to the liver where 
the first phase of the Plasmodium life cycle takes place. This is commonly known as 
the pre-erythrocytic or liver stage. 
 
Figure 2: Schematic illustration of the P. falciparum life cycle. Adopted from (White et 
al., 2014). 
 
In the liver, the sporozoites invade hepatocytes, multiply asexually by schizogony and 
mature into hepatic schizonts (White et al., 2014). The hepatic schizonts rupture and 
release approximately.10,000 to 30,000 merozoites into hepatic veins. This marks the 
end of a non-pathogenic pre-erythrocytic phase, 6−8 days post infection (White et al., 
2014, Vaughan et al., 2008). In P. vivax and P. ovale however, some sporozoites can 
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also enter into a dormant state, called hypnozoites and may remain latent for weeks 
to years (Robinson et al., 2015). 
 
The blood or erythrocytic cycle of the Plasmodium begins when merozoites invade 
erythrocytes in the hepatic veins. In the erythrocytes, merozoites reproduce asexually 
and develop via the ring stage (trophozoites) and mature into erythrocytic schizonts. 
The schizont subsequently rapture, releasing six to 32 daughter merozoites which 
invade other erythrocytes in circulation and initiate another erythrocytic cycle (White 
et al., 2014). A complete erythrocytic cycle occurs every 24 hours for P. knowlesi, 48 
hours for P. falciparum, P. vivax, and P. ovale, and 72 hours for P. malariae. Although 
most of the merozoites invading erythrocytes enter the erythrocytic cycle, a small 
proportion differentiates into dormant sexual stages, male and female gametocytes. 
The Anopheles mosquito then take up gametocytes concentrated in the skin capillaries 
during a blood meal (Kori et al., 2018).  
 
In the midgut of the mosquito, male and female gametocytes transform into 
microgametes and macrogametes, respectively. The fusion of the male and female 
gametes forms a diploid zygote (Phillips et al., 2017). The zygote sequentially 
develops through meiosis into a motile ookinete. The ookinete transverses the 
mosquito midgut epithelium and transform into the oocyte. Oocytes develop further 
into sporoblast which then gives rise to sporozoites via budding (Kori et al., 2018). 
Finally, sporozoites migrate to the mosquito salivary glands for transmission to the 
host in the next blood meal. Mosquitoes are infective 7 to 10 days after ingesting blood 
containing gametocytes (Phillips et al., 2017).  
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1.3. Clinical malaria 
Clinical or symptomatic malaria is caused by the continuous destruction of 
erythrocytes during the erythrocytic phase of the Plasmodium life cycle. Symptoms of 
the mildest form clinical malaria overlap with other febrile illnesses (Bartoloni and 
Zammarchi, 2012). These include chills, sweat, headaches, body aches, general 
malaise, nausea and vomiting (CDC, 2019, WHO, 2015). This form of malaria disease 
is referred to as uncomplicated malaria and it resolves rapidly once artemisinin−based 
combined therapy (ACT) is administered (WHO, 2015). If treatment is delayed 
however, uncomplicated malaria may progress to severe malaria or even death within 
a few hours (Trampuz et al., 2003).  
 
Severe malaria is mostly caused by P. falciparum and in rare occasions result from P. 
vivax and P. knowlesi infections (WHO, 2015). It develops three to seven days after 
the onset of fever and manifest as serious organ failure or hematologic/metabolic 
abnormalities. Complications of severe malaria include cerebral malaria, severe 
anaemia, hemoglobinuria, acute respiratory syndrome (ARDS), abnormal blood 
coagulation, acute kidney injury, hyperparasitemia, hypoglycaemia and metabolic 
acidosis (CDC, 2019, WHO, 2015). In most cases of severe malaria involve a 
combination of these complications with hypoglycaemia and metabolic acidosis being 
the most frequent. The propensity of an uncomplicated malaria case progressing to 
severe malaria is dependent on several factors, namely age (1 month to 5 years in 
malaria hyperendemic settings or >65 years old), pregnancy, antimalarial prophylaxis 
and immune status (Trampuz et al., 2003). Currently, the treatment for severe malaria 
is intravenous or intramuscular mono artesunate until a patient can tolerate oral 
treatment followed by a standard ACT regimen (WHO, 2015).  
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1.4. Malaria diagnosis 
1.4.1. Malaria rapid diagnostic tests 
In the search for an accurate, cost−effective, and field applicable test for malaria, 
numerous parasite detection methodologies have been developed that fall into three 
categories. These are molecular tests, serological tests and microscopy (Tangpukdee 
et al., 2009). Currently, rapid diagnostic tests (RDT) are the most widely used test for 
malaria diagnosis, particularly in resource−limited settings where good quality 
microscopy (the gold standard) barely exists (Mukkala et al., 2018). This is because 
they are cost−effective, easy to use, fast and do not require electricity (WHO, 2015). 
Furthermore, RDT diagnostic performance is comparable to routine microscopy. 
 
RDTs are ready−to−use lateral flow immunochromatographic tests that use 
monoclonal antibodies (mAbs) to detect malaria parasite antigens, namely P. 
falciparum histidine−rich protein 2 (PfHRP2), parasite lactate dehydrogenase (pLDH) 
and aldolase. Targeting these antigens allows identification of infections caused by 
any Plasmodium (pan) or related species. Detection of pLDH or aldolase identifies 
infections caused by all human malaria parasites. PfHRP2 and Pf−pLDH are specific 
for P. falciparum whereas Pv−pLDH is specific for P. vivax infection. Currently, over 
200 different RDT products are commercially available. Some detect a single antigen 
while others target a combination of Plasmodium genus− and species−specific 
antigens. Ninety per cent of RDT that are currently in use target PfHRP2.  
 
RDTs for malaria are made of a nitrocellulose strip enclosed in a plastic cassette. The 
strip is impregnated with antibodies. Figure 3 shows a schematic illustration of the 
principle of RDTs. Briefly, finger−prick blood (three blood drops) and a buffer are 
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added to the sample and buffer pads, respectively (Maltha et al., 2013). The buffer 
lyses the red blood cells, releasing Plasmodium antigens which subsequently bind to 
mAbs conjugated with colloidal gold. 
Figure 3: An illustration of the principle of RDTs. Adopted from (Bell et al., 2006) 
The parasite antigen−antibody−conjugate complex migrates along the nitrocellulose 
strip by capillarity until it is bound by immobilised antibodies (test line). The excess 
complexes and conjugated mAbs move further until they reach and bind to 
immobilised goat-raised anti−mouse antibodies (control line). The binding of 
antigen−antibody−conjugate complexes and conjugated mAbs at the test line and 
control line concentrate the conjugate signal, thereby generating coloured lines. 
Development of the control line only is interpreted as a malaria negative result 
whereas the development of the control and test line(s) is interpreted as a malaria 
positive result. The test results are obtained within 15−20 minutes. 
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Kenya adopted RDTs for malaria in 2012 and has since become heavily dependent 
on these tests for the management of malaria cases. PfHRP2 detecting RDTs are 
preferred in sub−Saharan Africa, including Kenya, due to the predominance of P. 
falciparum and acceptable diagnostic performance relative to routine microscopy (Wu 
et al., 2015, Gatton et al., 2015). However, there is an increasing concern on the 
suitability of PfHRP2−based RDTs after it became apparent that parasite genetics 
influence the test’s sensitivity (Baker et al., 2005, Gamboa et al., 2010). 
 
1.4.2. P. falciparum histidine−rich proteins 2 and 3 
PfHRP2 is a water−soluble and a heat stable protein expressed exclusively by P. 
falciparum. Although the function of PfHRP2 in P. falciparum is still unclear, it is 
hypothesised to be involved in hemozoin and actin formation, glycosaminoglycan 
binding, T-cell suppression, the structural modification of P. falciparum−infected 
erythrocytes, pathology and procoagulation (Sullivan et al., 1996, Benedetti et al., 
2003, Ndonwi et al., 2011, Pal et al., 2016). PfHRP2 is encoded by a gene (pfhrp2; 
PF3D7_0831800) located in the sub-telomeric region of chromosome 8. pfhrp2 has 
two exons, the first exon encodes a signal peptide and the second exon encodes a 
repetitive peptide, which mainly comprises of contiguous repeats with three amino 
acids, namely histidine, alanine and aspartic acid (Rock et al., 1987, Howard et al., 
1986). A total of 20 different PfHRP2 amino acid repeat types have been identified to 
date and numerically coded as repeat types 1 to 14 and 19 to 24 (Baker et al., 2005, 
Baker et al., 2010). These motifs vary in length and amino acid sequence as illustrated 
in Figure 4 (Bharti et al., 2017). 
 
9 
 
 
Figure 4: Schematic diagram showing the organisation of amino acid repeat types in 
P. falciparum histidine−rich protein 2 (a) and P. falciparum histidine−rich protein 3 (b 
and c). Broken line (black line) shows amino acid repeat types shared by PfHRP2 and 
PfHRP3. Adopted and modified from (Bharti et al., 2017). 
 
P. falciparum isolates exhibit extensive PfHRP2 diversity within and between parasite 
populations (Baker et al., 2005). The high antigenic diversity emanates from variation 
in the number, occurrence and structural organisation of amino acid repeat types. Most 
of the isolates from malaria−endemic regions have distinct amino acid repeat profile 
with Peruvian isolates being the least diverse (Baker et al., 2005, Baker et al., 2010). 
Variability in amino acid repeat profile may alter PfHRP2 detectability by RDTs as 
exemplified by differential PfHRP2-mAb reactivity among P. falciparum isolates from 
different geographical areas (Lee et al., 2012, Lee et al., 2006). PfHRP2 diversity is 
therefore suggested to be a plausible explanation for any observed difference in RDT 
sensitivity among different settings (Baker et al., 2005).  
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Analyses of the relationship between individual PfHRP2 repeat types per isolate and 
RDT performance revealed that the number of repeat types 2 and 7 could influence 
RDT sensitivity (Baker et al., 2005). In addition, a binary logistic regression model, 
also known as Bakers’ regression model, demonstrated that low values (<43) of the 
number of repeat type 2 multiplied by the number of repeat type 7 (type 2 × type 7) 
could predict RDT false negativity at <250 parasites/µl (Baker et al., 2005). Application 
of this model in Uganda and Senegal showed that type 2 × type 7 below 43 could 
reduce RDT sensitivity and cause RDT false negativity in field settings (Wurtz et al., 
2013a, Kumar et al., 2012). However, a larger study showed no association thereof 
and thus indicated that Bakers’ model cannot exclusively explain RDT false negativity 
(Baker et al., 2010). Other factors such as suboptimal levels of PfHRP2 should 
therefore be considered for decline in RDT sensitivity (Baker et al., 2011, Gatton et 
al., 2015, Plucinski et al., 2019). 
 
The most apparent cause of RDT negativity is pfhrp2 deletion. P. falciparum isolates 
lacking pfhrp2 were first observed in the Peruvian Amazon (Gamboa et al., 2010) and 
later in other countries among Africa, Asia, South and Central America (Gendrot et al., 
2018). pfhrp2 deletion is usually suspected when a P. falciparum−infected patient test 
negative for PfHRP2, despite being positive for pan− or Pf−pLDH. In addition, pfhrp2 
deletion can also be suspected when the positive rate of microscopy is ≥10 to 15% 
higher than PfHRP2−based RDT (WHO, 2016). The WHO recommends the 
replacement of PfHRP2 RDTs with non-PfHRP2 RDTs only when the national 
prevalence of pfhrp2 deletion exceeds five percent (WHO, 2017). The prevalence of 
parasites lacking pfhrp2 vary greatly within and between regions. Reports published 
so far show high prevalence in some South American countries, thereby rendering 
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PfHRP2−based RDTs unsuitable for falciparum malaria diagnosis, especially in the 
Peruvian Amazon. pfhrp2 deletion in Africa and Asia occurs at low prevalence (<10%) 
except in Ghana (36%) and Rwanda (23%) (Amoah et al., 2016, Kozycki et al., 2017, 
Gendrot et al., 2018, Kobayashi et al., 2019). P. falciparum isolates lacking pfhrp2 
have also been identified in a few samples (9%) collected in 2014 in Mbita, western 
Kenya (Beshir et al., 2017). 
 
Since PfHRP2 and P. falciparum histidine−rich protein 3 (PfHRP3; also expressed 
exclusively by P. falciparum; PF3D7_1372200; Figure 4) are structurally homologous, 
mAbs targeting PfHRP2 can cross-react with PfHRP3 and aid detection of pfhrp2 
deficient parasites (Lee et al., 2006, Rock et al., 1987, Wellems and Howard, 1986). 
However, this occurs at parasite densities >1000 parasites/µl and may not avert RDT 
false negativity due to pfhrp2 deletion. The existence of pfhrp3 deletion in many 
geographical areas at frequencies higher than pfhrp2 deletion and the presence of P. 
falciparum isolates lacking both pfhrp2 and pfhrp3 threaten management of malaria 
cases (Gendrot et al., 2018). This also raises important questions on the origin and 
spread of P. falciparum isolates lacking pfhrp2/3.  
 
Studies conducted so far show that pfhrp2 deletion originated from multiple genetic 
events (Akinyi et al., 2013). The introduction and successful establishment of pfhrp2 
negative parasites in a given geographical area is hypothesised to be influenced by 
parasite genetic diversity and malaria treatment rate (Gatton et al., 2017). In areas 
where pfhrp2 deficient parasites occur, the commonly used PfHRP2−based RDTs will 
fail to identify these cases and may contribute towards increasing the prevalence of 
pfhrp2 lacking P. falciparum (Gatton et al., 2017, Watson et al., 2017). In addition, low 
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or reducing malaria endemicity along with the coexistence of pfhrp2/3 deletion in P. 
falciparum drug resistant strains and insecticide−resistant Anopheles mosquitoes 
could accelerate selection and/or spatial distribution of P. falciparum isolates lacking 
pfhrp2/3. This suggests that changes in P. falciparum diversity and population 
structure in response to control measures may have an indirect impact on malaria 
RDTs. In view of the high dependence on PfHRP2−based RDTs, particularly in areas 
where P. falciparum prevalent such as Kenya, analyses of RDT performance, pfhrp2/3 
diversity and P. falciparum genetic diversity and population structure are of great 
public health importance. The present thesis presents data required to refine, adapt 
and improve malaria control strategies in Kenya. 
 
1.5. Scope and specific objectives 
This thesis aimed to re-evaluate the performance of RDT by microscopy and 
polymerase chain reaction methodologies and describe the distribution and diversity 
of P. falciparum histidine−rich proteins 2 (PfHRP2) and 3 (PfHRP3) in Kenya. 
Furthermore, the genetic diversity and population structure of P. falciparum 
populations from Kenyan-Ugandan border areas were analysed by genotyping P. 
falciparum−specific neutral microsatellites. The present thesis is structured as three 
independent chapters based on three research articles published in peer−reviewed 
journals. I investigated three specific objectives: 
1. Comparative evaluation of a PfHRP2/pLDH malaria RDT with microscopy and 
nested PCR methodologies. 
2. Genetic diversity of P. falciparum histidine rich proteins (PfHRP2 and 3) from 
Western and Coastal Kenya. 
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3. Understanding the genetic variability and population structure of P. falciparum 
isolates in the Kenyan-Ugandan border using neutral microsatellites. 
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2. RESULTS AND DISCUSSION 
 
 
 
2.1. Chapter 1: Comparative evaluation of PfHRP2/pLDH malaria RDT with 
microscopy and nested PCR methodologies 
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A B S T R A C T
Rapid diagnostic tests (RDT) are valuable tools that support prudent and timely use of antimalarial drugs,
particularly if reliable microscopy is not available. However, the performance and reliability of these tests vary
between and within geographical regions. The present study evaluated the performance of routine malaria RDT
in Kenyan febrile patients in Busia County, Kenya. A cross sectional study design was employed to recruit febrile
patients attending health facilities between August and November 2016. A total of 192 febrile patients who were
slide positive and negative were evaluated for their infection status by nested PCR and RDTs (PfHRP2/pLDH). In
addition, P. falciparum diversity of the histidine-rich proteins 2 and 3, that inﬂuences the RDT test results were
determined. All individuals were P. falciparum positive. Among the investigated 192 febrile patients, 76 (40%)
were positive by microscopy, 101 (53%) by RDTs and 80 (42%) were PCR positive. The performance of the
CareStart™ HRP2/pLDH (pf) RDTs was better than microscopy (Sensitivity 94%; Speciﬁcity 75%) and Nucleic
acid testing (sensitivity 95%, speciﬁcity 77%) with high negative predictive values, indicating the suitability of
the RDT in routine practice. Speciﬁc pfhrp2/pfhrp3 deletions shown to associate with RDT false negativity was
not observed. However, high genetic diversity among pfhrp2 gene was observed. Eleven new PfHRP2 and nine
PfHRP3 repeats were observed. False positivity by microscopy and under reporting of infections may thus be a
barrier in malaria control and elimination programs. The HRP2/pLDH(Pf) based RDT yet demonstrate to be an
eﬀective tool for malaria surveillance program.
1. Introduction
Reduction of the malaria burden over the last decade has renewed
eﬀorts towards its eventual elimination. In 2017, the World Health
Organisation (WHO) estimated that 216 million malaria cases and
445,000 deaths occurred in 2016 [1], representing a signiﬁcant decline
in new cases (21%) and deaths (29%) compared to 2010 estimations.
Despite being treatable, malaria continues to devastate developing
countries, especially in sub-Saharan Africa.
In Kenya, malaria accounts for 18% of outpatient consultations and
6% of hospital admissions with children below 5 years and pregnant
women being most aﬀected [2]. The objective of the Kenyan national
malaria control programme (NMCP) is to have all malaria suspected
cases tested and promptly treated with eﬀective drugs [3]. In a move to
boost malaria testing, the Kenyan NMCP introduced malaria rapid di-
agnostic tests (RDT) in 2012 [4]. Diagnosing of malaria in Kenya by
microscopic examination of blood smears has been reduced in favour of
RDT usage [2]. This trend is largely driven by microscopy's dependence
on electricity, skilled manpower and scarcity of good-quality reagents
and microscopes.
Malaria RDTs are lateral ﬂow immunochromatographic tests using
monoclonal antibodies (MAbs) to detect Plasmodium antigens, namely
https://doi.org/10.1016/j.parint.2018.08.007
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⁎ Corresponding author at: Institute of Tropical Medicine, Wilhelmstrasse 27, 72074 Tübingen, Germany.
E-mail address: velavan@medizin.uni-tuebingen.de (T.P. Velavan).
Parasitology International 67 (2018) 793–799
Available online 20 August 2018
1383-5769/ © 2018 Elsevier B.V. All rights reserved.
T
histidine-rich protein 2 (PfHRP2), lactate dehydrogenase (LDH) and
aldolase [5]. By targeting these antigens, infections caused by any
human Plasmodium species (LDH or aldolase) and by distinct species
(PfHRP2 or PfLDH for P. falciparum and PvLDH for P. vivax) may be
identiﬁed [6]. RDTs vary depending on manufacturers, with some de-
tecting Plasmodium (pan) antigen in combination with one or two
species-speciﬁc antigens [7]. Others detect only a speciﬁc Plasmodium
species infection with those based on the detection of PfHRP2 con-
stituting 90% of RDTs currently used [8]. Testing is fast with visualized
results obtained within 15–20min. The low cost, ease of use and per-
formance make these tests a key pillar in malaria control program.
Malaria diagnosis in Kenya is heavily reliant on PfHRP2-based
RDTs. However, the performance of these RDTs increasingly faces re-
duced sensitivity, a situation that may worsen as prevalences of low
parasitemia malaria increase with the improvement of malaria control
strategies. Routine RDT evaluation by WHO's Foundation for Innovative
New Diagnostics (FIND) and adoption of good manufacturing practices
have helped to reduce the impact of RDT product quality on perfor-
mance [5,9].
However, the eﬀect of parasite factors on PfHRP2-based RDTs is yet
to be deﬁned in many malaria-endemic countries. PfHRP2 is mainly
composed of three amino acids (alanine, histidine and aspartate) and it
is homologous to PfHRP3 [10,11]. The amino acid repeat proﬁle of
PfHRP2 varies extensively within and between countries unlike LDH
[12–14]. As a result of this, PfHRP2 diversity has been identiﬁed as a
key contributor for RDT sensitivity [15]. This is supported by the dif-
ferential binding of MAbs to PfHRP2 from diﬀerent geographical areas
[16,17]. PfHRP2 diversity has also been identiﬁed as the potential
cause of RDT false negativity, particularly when parasitemia is ≤250
parasites/μl. In a case study from Senegal, a low number of two PfHRP2
amino acid repeat motifs (types 2: AHHAHHAAD and type 7: AHHAAD)
was identiﬁed as the cause of delayed falciparum malaria diagnosis
[18]. The correlation of the number of these two motifs with RDT's limit
of detection and the lack thereof have also been reported [12,15,19].
The signiﬁcance of pfhrp2 deletion in falciparum malaria diagnosis
is unequivocal. In South America's Peruvian Amazon high rates of
pfhrp2/3 deletion rendered PfHRP2-based RDTs to be inappropriate for
falciparum malaria diagnosis [20]. A similar situation has been re-
ported from other parts of South America, Asia and Africa, however, at
lower prevalences [21–24]. The recent observation of P. falciparum
lacking pfhrp2 in Rwanda, the Democratic Republic of Congo, Eritrea as
well as Kenya raises important questions on the suitability of PfHRP2-
based RDTs [25–29]. Where pfhrp3 is expressed and pfhrp2 is lacking,
isolates are detectable provided parasitemia is ≥1000 parasites/μl.
This phenomenon was reported in a genomic study from Kenya; eight
isolates lacking pfhrp2 were detectable by PfHRP2-based RDTs [29].
However, this stands to be reversed as the prevalence of pfhrp3 devoid
isolates increases and parasitemia decreases. The lack of information on
the geographical distribution of pfhrp2/3 devoid parasites and PfHRP2-
PfHRP3 diversity in Kenya clearly shows that RDT performance and the
relevant parasite genetic background needs close monitoring.
Against this background, we re-evaluated the performance and re-
liability of RDT against microscopy and nested PCR for their sustained
use in Malaria control program. In addition, we analysed the diversity
of PfHRP2 and its homologue PfHRP3, for any pfhrp2/pfhrp3 deletions
shown to associate with RDT false negativity.
2. Materials and methods
2.1. Ethical approval
The study was approved by the Scientiﬁc and Ethics Review Unit
(SERU) of Kenya Medical Research Institute (KEMRI), Nairobi (KEMRI/
SERU/0152/3250). Written informed consent was obtained from each
participant (for children provided by parents/guardians). All experi-
ments were performed in accordance with good laboratory practice
(GLP) guidelines.
2.2. Study site and sample collection
The study was conducted between August and November 2016 in
the Matayos Health Centre in Busia County, a malaria endemic site
approximately 80 km northeast of Lake Victoria, Kenya. Busia is in-
habited by 743,946 people with children< 5 years accounting for 18%
[30]. It has a tropical climate (annual rainfall 750–2000mm) with
average temperatures of 21–27 °C [31]. These conditions are ideal for
vector breeding which sustain perennial malaria transmission. Peak
incidences occurs shortly after the long (March–June) and short (Oc-
tober–November) rains with increasing vector populations. Although
transmission in this region is predominantly by Anopheles gambiae sensu
stricto, An. arabiensis and An. funestus are also present at lower occur-
rences [32]. In 2014, malaria parasitemia prevalence was estimated to
be between 20% and 40% in the Lake Victoria region, mainly caused by
P. falciparum [33]. Coinfections of P. falciparum and other parasite
species (P. ovale and/or P. malariae) also occur in this region. P. vivax
does not occur [34]. Patients with fever, irrespective of age, were asked
to participate in the study. A ﬁnger−prick blood sample was collected
for thick and thin blood smears, dried blood spots on Whatman™ ﬁlter
papers, and for CareStart™ HRP2/pLDH(Pf) RDT testing. From each
participant, three to four drops of blood (40–50 μl) were applied onto a
Whatman™ ﬁlter paper and allowed to dry at ambient temperature for
at least one hour before being individually packed in a ziplock bag with
desiccant.
2.3. Malaria diagnosis
Malaria screening was performed by microscopy, PfHRP2/pLDH
(CareStart™, ACCESS BIO, INC, Korea) RDT and P. falciparum-speciﬁc
nested PCR. Diagnoses were made by two independent laboratory
technicians blinded to the study objective, clinical presentation of
participants and test results of either microscopy or RDT. Thick and thin
smears were Giemsa stained and examined (1000× magniﬁcation)
[35]. Parasitemia was recorded as number of parasites per 200 white
blood cells. Parasite densities were determined by multiplying para-
sitemia by 40, assuming that 1 μl blood contains 8000 WBCs.
Diagnosis by RDT was conducted using the PfHRP2/pLDH
(CareStart™, ACCESS BIO, INC, Korea) according to the manufacturer's
instructions. This RDT is a two band WHO prequaliﬁed test system,
with a 91% panel detection score (PDS) and < 1% false positive rate,
designed for detecting P. falciparum infections [9]. PDS is the propor-
tion of P. falciparum positive samples identiﬁed by all PfHRP2/pLDH
(CareStart™, ACCESS BIO, INC, Korea) RDT lots evaluated at 200
parasites/μl during the sixth round of WHO product testing of malaria
RDTs [9]. One of the test lines serves as control, while the second line
indicates the presence of P. falciparum. The RDT reaction is based on
two MAbs speciﬁc for P. falciparum antigens, namely the histidine-rich
protein 2 (PfHRP2) and lactate dehydrogenase (PfLDH). Results were
only considered valid if the control test line was clearly visible. If the
control line was not visible, testing was repeated. All cases positive by
RDT or microscopy were referred to the resident clinician for im-
mediate treatment with artemisinin combination therapy according to
local guidelines [36].
Genomic DNA was extracted from dried blood spots on Whatman™
ﬁlter paper (QIAamp DNA mini kit; Qiagen, Hilden, Germany) ac-
cording to the manufacturer's instructions. All samples were tested for
P. falciparum infection using a previously described nested PCR protocol
with a limit of detection of one parasite [37,38]. Brieﬂy, 1 μl of DNA
template was added to a PCR reaction mix containing 1× PCR buﬀer
(Qiagen, Hilden, Germany), 200 μM of each dNTPs, 1 unit of Qiagen
Taq DNA polymerase (Qiagen, Hilden, Germany), and 100 nM of each
primer in a volume of 20 μl. Plasmodium genus PCR reaction conditions
were: initial denaturation at 95 °C for 5 mins followed by a secondary
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denaturation step at 94 °C for 1min, annealing at 58 °C for 2 mins,
extension at 72 °C for 2 mins for 25 cycles and a ﬁnal extension at 72 °C
for 5 mins. P. falciparum speciﬁc PCR reactions were run for 30 cycles
using the same PCR conditions. Amplicons were visualized by 1.5%
agarose gel electrophoresis.
2.4. PCR ampliﬁcation of pfhrp2 and pfhrp3 exon 2
The ampliﬁcation of pfhrp2 (exon 2) and pfhrp3 (exon 2) was per-
formed using a previously described semi-nested PCR [15]. The PCR
master mix was prepared as required for P. falciparum nested PCR.
Conditions were initial denaturation at 94 °C for 5 mins followed by a
secondary denaturation step at 94 °C for 30 s, annealing at 50 °C for
50 s, extension at 72 °C for 1min and a ﬁnal extension at 72 °C for 10
mins. Primary and secondary PCRs were run with 27 and 32 cycles,
respectively. P. falciparum strains 3D7 (pfhrp2 and pfhrp3 positive), Dd2
(pfhrp2 negative and pfhrp3 positive) and HB3 (pfhrp2 positive and
pfhrp3 negative) were used as controls.
Amplicons were puriﬁed using Sephadex™ G-50 ﬁne DNA grade (GE
Healthcare, Buckinghamshire, UK) according to the manufacturer's in-
structions. Sequencing was carried out using secondary PCR primers
targeting the pfhrp2 and pfhrp3 exon 2 and the BigDye Terminator
v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA).
The BioEdit software was applied to assemble forward and reverse
nucleic acid sequences and to deduce amino acid sequences.
2.5. PfHRP2 diversity
PfHRP2 has a rich genetic diversity (amino acid repeats) and are
associated with RDT sensitivity. A total of 20 diﬀerent amino acid re-
peats are described [12,15]. Among these 20 amino acid repeats, any
changes in amino acid repeats (esp. repeat type 2: AHHAHHAAD and
repeat type 7: AHHAAD) was shown to associate with declined RDT
sensitivity as documented in other studies conducted across diﬀerent
geographical regions including South America, Africa, and Southeast
Asia [15,18,19].
Based on the PfHRP2 diversity, we classiﬁed our investigated
sample in four speciﬁc groups (Group A; B; I and C respectively). This
classiﬁcation (Bakers model) is based on multiplying the number of two
amino acid repeat types (numbers of type 2× numbers of type 7) as
described previously [15]. Based on this classiﬁcation, the groups were
classiﬁed as very sensitive (Group A; type 2× type 7;> 100), sensitive
(Group B; type 2× type 7; between 50 and 100), borderline or Inter-
mediate (Group I; type 2× type 7; between 44 and 49) and non-sen-
sitive (Group C; type 2× type 7;< 44) [15]. The PfHRP2− based RDT
false negativity rate was calculated, following Baker's regression model
(binary logistic regression), by determining the proportion of samples
with PfHRP2 types 2× type 7 < 44 [15]. The samples classiﬁed under
Group C served as an estimator for RDT false negativity (parasitemia
≤250 parasites/μl).
2.6. Multiplicity of infection (MOI)
The MOI was determined using a P. falciparum merozoite surface
protein 1− speciﬁc nested PCR (msp1; K1, MAD20 and R033 allelic
families) as described previously [39]. Malaria cases with only one al-
lele at each of the msp1 allelic family loci were regarded to be mono-
clonal infections whereas infections with more than one allele in at least
one msp1 allelic family locus were regarded to be polyclonal infections.
The total number of msp1 alleles were divided by the number of msp1
positive samples to determine the mean MOI. The percentage of
monoclonal infections was used to estimate the probability of identi-
fying isolates lacking pfhrp2 and/or pfhrp3.
2.7. Data analysis
Two-tailed Chi-square test was executed to compare the P. falci-
parum positivity rates. Microscopy results were used as gold standard.
The PfHRP2/pLDH RDT performance was assessed for sensitivity, spe-
ciﬁcity, positive predictive values (PPV) and negative predictive values
(NPV).
3. Results
A total of 192 febrile cases were recruited for evaluation of the
PfHRP2/pLDH RDT. The baseline characteristics have been described in
Table 1. Among the febrile individuals, P. falciparum was detected in
40% (n=76), 53% (n=101) and 42% (n=80) by microscopy, RDT
and nested PCR, respectively (Table 1). The detection rate of PfHRP2/
pLDH RDT was signiﬁcantly higher than by microscopy (p-value 0.01)
as well as by nested PCR (p-value 0.03). The P. falciparum detection
rates were similar between microscopy and PCR (p-value 0.67). All
cases were caused by P. falciparum mono-infection and there were no
invalid RDT results.
3.1. Performance of CareStart™ Malaria HRP2/pLDH(Pf) RDT
The CareStart™ Malaria HRP2/pLDH(Pf) RDT showed a similar
performance compared to microscopy and nested PCR (Table 2). Thirty-
three (17%) CareStart™ Malaria HRP2/pLDH(Pf) results were dis-
cordant with those of microscopy. Of the 33 discordant with
Table 1
Baseline characteristics of the study cohort.
Baseline study cohort details Value(s)
Mean age in years (Range) 14.4 (0.3–76)
Female-male ratio 2:1
Parasite geometric mean [parasites/μl; (Range)] 7773 (80–202,880)
Sample size (n) 192
Microscopy positive 76
PCR positive 80
RDT positive 101
RDT vs. microscopy [n (%)]
RDT positive−microscopy positive 72 (38)
RDT positive−microscopy negative 29 (15)
RDT negative−microscopy positive 04 (2)
RDT negative−microscopy negative 87 (45)
RDT vs. PCR [n (%)]
RDT positive−PCR positive 75 (39)
RDT positive−PCR negative 26 (14)
RDT negative−PCR positive 05 (3)
RDT negative−PCR negative 86 (45)
Microscopy vs. PCR [n (%)]
Microscopy positive−PCR positive 70 (36)
Microscopy positive−PCR negative 06 (3)
Microscopy negative−PCR positive 10 (6)
Microscopy negative−PCR negative 106 (55)
Note: RDT- Rapid diagnostic test; PCR- Polymerase chain reaction.
Table 2
Performance of the CareStart™ HRP2/pLDH (pf) RDT using Giemsa microscopy
and P. falciparum nested PCR as reference methods.
PfHRP2/pLDH RDT Performance Microscopy (95% CI) nested PCR (95% CI)
Sensitivity (%) 94.7 (87.1–98.6) 93.8 (86.01–97.9)
Speciﬁcity (%) 75 (66.1–82.6) 76.8 (67.86–84.2)
Positive predictive value (%) 71.3 (64.3–77.3) 74.3 (67.21–84.2)
Negative predictive value (%) 95.6 (89.3–98.3) 94.5 (87.98–97.6)
Agreement (%) 82.81 83.40
Kappa Value (κ) 0.66⁎ 0.68⁎
Positive likelihood ratio 3.79 (2.8–5.3) 4.04 (2.9–5.7)
Negative likelihood ratio 0.07 (0.07–0.2) 0.08 (0.03–0.2)
⁎ p-Value< .0001.
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microscopy, four were false negative (positive by microscopy and ne-
gative by RDT; 320 to 680 parasites/μl) and the remaining 29 were
false positive (negative by microscopy and positive by RDT). Using
nested PCR to resolve the discordance, 2 out of 4 RDT false negatives
tested positive and 7 out of 29 false positives were conﬁrmed to be true
positives. Against nested PCR, the agreement was 83% which re-
presented a discordance rate of 17% (Table 2). Overall, CareStart™ false
positive rate decreased from 25% to 23%, and the false negative rate
increased from 5% to 6% when nested PCR replaced microscopy as a
reference method.
3.2. PfHRP2 and PfHRP3 diversity
The exon 2 of both pfhrp2 (n=38) and pfhrp3 (n=49) were Sanger
sequenced. Amino acid sequences were deduced subsequently. The
length of the PfHRP2 amino acid sequence was between 244 and 330
and for PfHRP3 between 160 and 229 amino acids. Overall, we iden-
tiﬁed 20 previously described PfHRP2 amino acid repeat types and nine
PfHRP3 amino acid repeats (Table 3).
In PfHRP2, the repeat types 1,2,3,6,7,8,10 and 12 were observed to
be more frequent, whereas repeat types 13 (8%) and 14 (3%) were rare.
The repeat types 9 and 11 were absent in all isolates. Additionally,
eleven new PfHRP2 repeat types that have not been described
previously were identiﬁed at low frequencies (Table 3). The classiﬁ-
cation of PfHRP2 based on the product of the number of types 2 and 7
per isolate revealed that group A, B, I and C constituted 16% (6), 71%
(27), 5% (2) and 8% (3) respectively. Based on Baker's regression
model, we could predict that 8% of isolates (group C) in this study
would not be detected by PfHRP2-based RDTs, even at a parasite
density of ≤250 parasites/μl [15].
Eight out of nine repeat types previously reported to occur in
PfHRP3 were identiﬁed all isolates analysed as shown in Table 3 [12].
Type 2 was identiﬁed in one isolate only. In addition, nine PfHRP3 new
repeat types that have not been described previously were identiﬁed at
low frequencies (Table 3). Among the nine new amino acid repeats in
PfHRP3, the motifs AHQDH and LNAAN could not be categorized in
any of the pre-described repeat types. In addition, the newly identiﬁed
motif SHHDG was observed frequently in PfHRP3.
3.3. Multiplicity of infection (MOI)
Of the 80 P. falciparum conﬁrmed samples by nested PCR, msp1
allelic families were ampliﬁed in 66 (83%) samples. K1 (n=55; 83%)
was the most common allelic family followed by MAD20 (n=30; 45%)
and RO33 (n=23; 35%). Table 4 shows the occurrence of msp1 gen-
otypes in this study. The occurrence of mono-infection was 45% (30)
whereas the occurrence of polyclonal infections was 55% (36). Based
on the proportion of monoclonal infections, the estimated probability of
identifying isolates lacking pfhrp2 and/or pfhrp3 was 45%. The mean
MOI was 2.4 (95% CI: 2.0–2.7).
4. Discussion
Malaria RDTs are instrumental in increasing the proportion of suc-
cessful malaria case management [2]. P. falciparum histidine-rich pro-
tein 2 (PfHRP2)-based RDTs are the most commonly used systems for
malaria diagnosis. However, several reports on suspected sensitivity
issues due to the genetic diversity of the parasite underscores the need
to closely monitor the performance of PfHRP2-based RDTs.
CareStart™ Malaria HRP2/pLDH(Pf) showed a high agreement with
microscopy and nested PCR and an acceptable diagnostic performance,
consistent with previous studies [40,41]. Surprisingly, this test was
unable to identify four malaria cases with parasitaemia between 320
and 680 parasites/μl, despite being able to simultaneously detect pLDH.
Since parasitemia was above the limit of detection of RDTs (100
parasites/μl) and that two of four false negative cases were detected by
nested PCR, it is likely that the observed misdiagnosis was due to
methodological errors during testing. For instance, dispensing in-
suﬃcient sample and/or buﬀer volume, reading of test results too early
and/or reporting a faint test−line as negative may all be plausible
reasons [5].
The speciﬁcity and positive predictive value (PPV) of the CareStart™
Malaria HRP2/pLDH(Pf) RDT were low and caused by false positivity.
This is characteristic of PfHRP2-based RDTs in endemic settings [5].
Persistence of PfHRP2 after treatment of malaria and parasite clearance
Table 3
Distribution of the number of PfHRP2 and PfHRP3 amino acid repeat types.
Antigen Repeat types Amino acid repeat Observed
repeats
Occurrence (%)
PfHRP2 Type 1 AHHAHHVAD 0–7 92
AHHAHYVAD (New) 1 4
Type 2 AHHAHHAAD 8–15 100
Type 3 AHHAHHAAY 0–4 84
Type 4 AHH 0–3 40
ASH (New) 1 3
THH (New) 1 3
AAH (New) 1 5
Type 5 AHHAHHASD 0–2 68
AHHAHHAPD (New) 1 3
Type 6 AHHATD 1–6 100
APHATD (New) 1 3
Type 7 AHHAAD 3–12 100
AHHAPD (New) 1 3
Type 8 AHHAAY 1–2 100
AHHASY (New) 1 3
Type 10 AHHAAAHHATD 0–3 82
AHHAATHHATD
(New)
1 3
Type 12 AHHAAAHHEAATH 0–1 90
AHHAAAHHEAATP
(New)
1 3
Type 13 AHHASD 0–1 8
Type 14 AHHAHHATD 0–1 3
Type 19 AHHAA 0 0
THHAA (New) 1 3
PfHRP3 Type 1 AHHAHHVAD 0–3 96
Type 2 AHHAHHAAD 0–1 2
Type 4 AHH 1 98
Type 7 AHHAAD 1 100
Type 15 AHHAHHAAN 1 100
Type 16 AHHAAN 7–16 100
AHHAAK (New) 1 2
SHHAAN (New) 1 2
Type 17 AHHDG 2–9 100
QHHDG (New) 1 2
SHHDG (New) 1 8
THHDG (New) 1 2
AHHDE (New) 1 2
Type 18 AHHDD 1–3 100
EHHDD (New) 1 2
Type 20 SHHDD 1 100
Type
(unknown)
AHQDH (New) 1 2
LNAAN (New) 1 2
Table 4
Occurrence of P. falciparum msp1 genotypes.
msp1 genotype Genotype occurrence n (%)
K1 20 (30)
R033 3 (5)
MAD20 7 (11)
K1/RO33 10 (15)
K1/MAD20 16 (24)
MAD20/RO33 3 (5)
K1/MAD20/RO33 7 (11)
Total 66 (100)
msp1: merozoite surface protein 1.
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is a major cause of low speciﬁcity [42]. Other sources of PfHRP2 in-
clude expression by gametocytes and/or asexual stages at submicro-
scopic levels [5,6,43]. As a result, it is impossible for the CareStart™
Malaria HRP2/pLDH(Pf) test or any other PfHRP2-based RDT to re-
liably distinguish between active infection and positivity due to per-
sistence of PfHRP2. This may be circumvented by detecting Plasmodium
LDH or aldolase. Nevertheless, detection of PfHRP2 and PfLDH by the
CareStart™ Malaria HRP2/pLDH(Pf) RDT did not improve its speciﬁcity
in the present study.
The sensitivity of a reference method has a direct impact on the
performance of diagnostic tests under investigation [40]. Our reference
method, microscopy, had a detection limit of 80 parasites/μl. This could
have lowered the CareStart™ RDT speciﬁcity because of submicroscopic
malaria infections with detectable PfHRP2-based RDT [44]. The de-
tection of seven P. falciparum cases by nested PCR and RDT missed by
microscopy favour this possibility and reaﬃrmed that microscopy is an
imperfect gold standard [45]. Evaluation of the CareStart™ Malaria
HRP2/pLDH(Pf) RDT against nested PCR revealed minimal changes
only of sensitivity and speciﬁcity. This is inconsistent with previous
studies; in fact, the nested PCR used as a reference here had a similar
performance compared to microscopy [40,46]. Important to note is that
CareStart™ Malaria HRP2/pLDH(Pf) exhibited high negative predictive
values (NPV) and a low negative likelihood ratio as reported previously
[40,41,47], indicating that negative CareStart™ Malaria HRP2/pLDH
(pf) results can be relied on with suﬃcient conﬁdence. In spite of a
small sample size (192), these ﬁndings are signiﬁcant, as the P. falci-
parum prevalence in this study (40%) was within the prevalence range
(20 to 40%) reported in Western Kenya [33]. However, low speciﬁcity
of the CareStart™ Malaria HRP2/pLDH(Pf) test may lead to over-
prescription of antimalarial drugs and/or complicate diagnoses of other
febrile conditions.
The degree of parasitemia is currently insuﬃcient to explain
PfHRP2-based RDT performance variation in malaria diagnoses
[19,24,26,48]. Successful exon 2 ampliﬁcation of pfhrp2 and pfhrp3 in
all P. falciparum positive samples eliminated gene deletion as cause of
false negativity. However, the recent identiﬁcation of P. falciparum
lacking pfhrp2/3 in Kenya, the Democratic Republic of Congo, Eritrea
and Rwanda raise fundamental questions about the sustainability of
PfHRP2− detecting RDTs in East Africa [25–27,29]. In other parts of
the world, this phenomenon is indisputable, with countries such as Peru
having a prevalence of 41% [20]. It is important to note that the
probability of identifying isolates lacking pfhrp2 and/or pfhrp3 in the
present study may have been reduced by P. falciparum polyclonal in-
fections as reported recently [49] and the analysis of a rather small
number of isolates. In view of the higher proportion of polyclonal in-
fections than monoclonal infections, the probability of identifying iso-
lates lacking pfhrp2 and/or pfhrp3 in this study was 45%.
The diversity of PfHRP2 may also determine RDT sensitivity
[15,18,19]. We observed high PfHRP2 diversity among our Kenyan
isolates. The repeat types identiﬁed here have also been detected in
other geographical regions except for types 9 and 11 which have been
detected rarely only so far [12,14,15,22,50,51]. Ten PfHRP2 repeat
types (type 1 to 8, 10 and 12) identiﬁed were highly prevalent. The
similarity in the occurrence of these repeat types between our study and
previous studies suggests temporal persistence of similar PfHRP2 epi-
topes despite the observed antigen diversity. This implies that diﬀerent
PfHRP2-based RDT products are detecting homologous epitopes, par-
ticularly because there is a limited number of PfHRP2− speciﬁc MAbs
available at present [16,17]. This may explain the similarity of the
sensitivity of CareStart™ RDT in this study with that of other RDT
products evaluated previously [40,41].
Repeat types 2 and 7 constitute> 50% of repeat types found in
PfHRP2 and are likely to be the main contributor of the epitopes in-
volved in PfHRP2 detectability [15]. In 2005, Baker et al. published the
ﬁrst report linking RDT sensitivity to the product of the number of these
two repeat types (type 2× type 7). They showed, using a binary logistic
regression model (Baker's regression model), that PfHRP2− based
RDT's failure to detect P. falciparum laboratory strains at a parasitemia
≤250 parasites/μl was due to type 2× type 7 that was< 43 and
suggested that this model could be used to predict the false negative
rate of RDTs targeting PfHRP2 in the ﬁeld [15]. Evaluation of this
model in ﬁeld settings has provided conﬂicting results [12,18,19]. The
present study did not investigate the impact of type 2× type 7 below
43 on CareStart™ Malaria HRP2/pLDH(Pf) RDT false negativity rate
(5%) when microscopy was used as a reference, because this RDT de-
tects both PfHRP2 and pLDH in a single test band. Other reasons are
that the PfHRP2 diversity of two RDT undetected isolates were not
investigated because sequencing of the pfhrp2 could not be achieved
despite repeated attempts. The remaining two isolates had>43 type
2× type 7 at a parasitemia≥320 parasites/μl, which is above the RDT
limit of detection. Nevertheless, this study predicts that 8% of isolates
from western Kenya would remain undetected at a parasitemia of≤250
parasites/μl. These ﬁndings are comparable to previous studies using
isolates collected from Senegal (7%) and Madagascar (9%) and globally
(16%) [13,14,22].
Unlike PfHRP2, PfHRP3 was less diverse as demonstrated by the
presence of all nine repeat types described previously [12]. The number
of repeat types 15, 17 and 18 per sample varied the most, in line with
previous reports [15,22,52]. Repeat type 2 is rarely detected in PfHRP3
and its presence in one isolate in our study was surprising. In 2010,
Baker et al. reported complete absence of repeat type 2 among isolates
from Africa, Asia (except a few isolates from the Philippines), South-
west Paciﬁc as well as Central and South America [12]. The Baker et al.
study was based on 27 African isolates. Of this, only six isolates origi-
nated from Kenya. This is the only study to date describing PfHRP3
diversity in Kenya to the best of our knowledge. Our study shows that
there is a small population of P. falciparum expressing PfHRP3 with
repeat type 2. This suggests that presence of type 2 in western Kenya
may have occurred recently. The presence of the three repeats types 1, 4
and 7 in PfHRP3 and PfHRP2 shows that CareStart™ Malaria HRP2/
pLDH(Pf) can detect PfHRP3. This is useful in cases where P. falciparum
isolates without pfhrp2 occur provided parasitemiais is ≥1000 para-
sites/μ [16,29].
Seventeen of 20 new repeat type observed here originate from a
single amino acid replacement of previously published repeat se-
quences. Although this is the ﬁrst observation among African isolates,
similar observations were made in Asian isolates [50,52]. Only four
repeat type variants identiﬁed in these two studies were identiﬁed in
our study, including the motifs THH, AHHAPD, AHHASY and SHHDG.
The ﬁrst three motifs were identiﬁed in PfHRP2, and SHHDG was
present in PfHRP3. The observation of repeat type variants raises
questions on their future impact on the performance of PfHRP2-based
RDTs. However, the low occurrence of repeat type variants suggests
that they may not have a signiﬁcant impact on RDT performance.
5. Conclusion
The high false positive rate indicates that the CareStart™ HRP2/
pLDH(Pf) RDT may lead to over-prescription of antimalarial drugs and
overestimation of the malaria burden. The management of other febrile
diseases in western Kenya may, thus, be neglected or, at least, aﬀected.
Examining for other fever etiologies is required to promote prudent use
of antimalarial drugs. The high negative predictive value shows that
this RDT can be used to rule out falciparum malaria and be an eﬀective
tool for malaria surveillance program.
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Plasmodium falciparum histidine-
rich protein (PfHRP2 and 3) 
diversity in Western and Coastal 
Kenya
David Nderu1,2, Francis Kimani3, Kelvin thiong’o3, Evaline Karanja4, Maureen Akinyi3, 
edwin too3, William Chege3, Eva Nambati3, Christian G. Meyer1,5,6 & 
Thirumalaisamy P. Velavan1,5,6,7
Plasmodium falciparum histidine-rich proteins 2 (PfHRP2) based RDTs are advocated in falciparum 
malaria-endemic regions, particularly when quality microscopy is not available. However, diversity and 
any deletion in the pfhrp2 and pfhrp3 genes can affect the performance of PfHRP2-based RDTs. A total 
of 400 samples collected from uncomplicated malaria cases from Kenya were investigated for the amino 
acid repeat profiles in exon 2 of pfhrp2 and pfhrp3 genes. In addition, PfHRP2 levels were measured in 
96 individuals with uncomplicated malaria. We observed a unique distribution pattern of amino acid 
repeats both in the PfHRP2 and PfHRP3. 228 PfHRP2 and 124 PfHRP3 different amino acid sequences 
were identified. Of this, 214 (94%) PfHRP2 and 81 (65%) PfHRP3 amino acid sequences occurred only 
once. Thirty-nine new PfHRP2 and 20 new PfHRP3 amino acid repeat types were identified. PfHRP2 
levels were not correlated with parasitemia or the number of PfHRP2 repeat types. This study shows the 
variability of PfHRP2, PfHRP3 and PfHRP2 concentration among uncomplicated malaria cases. These 
findings will be useful to understand the performance of PfHRP2-based RDTs in Kenya.
Malaria associated morbidity and mortality has steadily declined in recent years due to increased use of bed nets 
and other pertinent control measures1,2. Although malaria is an easily treatable parasitic disease, the rapid devel-
opment of antimalarial drug resistance considerably threatens control efforts.
Microscopic examination of stained blood smears continues to serve as the gold standard for malaria diagno-
sis3. However, it is not readily available in resource-limited areas due to the scarcity of skilled personnel, reliable 
electricity supply, good quality reagents and infrastructure3. The WHO and national malaria control programmes 
(NMCPs) have put in place strategies to circumvent this pitfall. One of these strategies is compulsory malaria 
testing by appropriate test systems, including rapid diagnostic tests (RDTs) prior to the prescription of antima-
larial drugs.
Discrepancies in the performance of antigen detecting tests are attributed to a combination of factors such 
as parasite levels, interpretation of RDT results and/or the handling and storage of RDT kits. However, some of 
the inconsistencies observed with results from Plasmodium falciparum histidine-rich protein 2 (PfHRP2)-based 
RDTs may also be explained by the deletion of the pfhrp2 gene and its structural homologue, pfhrp3, in some 
parasite isolates.
In the 1990s, the first hand−held immunochromatographic malaria diagnostic test known as rapid diag-
nostic test (RDT), was developed to address the shortcomings of microscopy4. RDTs detect Plasmodium anti-
gens using monoclonal antibodies (MAbs) impregnated on a nitrocellulose membrane5. About 10 µl of blood 
is required to perform the test. The antigens targeted by commercially available RDTs include P. falciparum 
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histidine-rich protein 2 (PfHRP2), lactate dehydrogenase (LDH) and aldolase. PfHRP2 is P. falciparum-specific, 
aldolase is genus-specific, and LDH is available in three formats, namely P. falciparum-specific, P. vivax-specific 
and genus-specific6.
Currently, there are more than 200 commercially available malaria RDT brands. The RDTs differ between 
manufacturers, depending on the antigen or combination of antigens that can be detected7. The WHO recom-
mendation on the RDT format to be used in a given geographical area depends on the predominant Plasmodium 
species. For regions where P. falciparum is predominant such as sub-Saharan Africa, the WHO recommends the 
use of PfHRP2-based RDTs. Eighty-three percent of RDTs procured in 2016, globally, were supplied to African 
countries2. Ninety percent of these RDTs target PfHRP28.
The national malaria control programme of Kenya adopted the use of PfHRP2 detecting RDTs in 20129,10. 
Future use of this test is threatened in many malaria-endemic areas including Kenya by the deletion of the gene 
coding for P. falciparum PfHRP2 and extensive antigen diversity that contributes to variation of the sensitivity 
of these tests11–17. There has been a considerable increase in the number of countries with P. falciparum isolates 
devoid of pfhrp2 and/or pfhrp3 over the last eight years. Recent entrants include Mozambique, Eritrea, Rwanda 
and Kenya8,12,15,18–23. It is therefore important to monitor parasite factors that can undermine malaria RDT-based 
diagnosis and, in the long run, safeguard the efficacy of antimalarial drugs and promote prompt and appropriate 
management of febrile illnesses.
The present study aimed to investigate the diversity of PfHRP2 and its homologue PfHRP3 as well as variation 
of PfHRP2 levels in uncomplicated malaria cases from two malaria-endemic regions located in Western and 
Coastal Kenya.
Results
Exon 2 of both pfhrp2 and pfhrp3 was detected in all the 400 samples analysed in this study. Of this, 244 pfhrp2 
and 267 pfhrp3 PCR products were successfully sequenced and their amino acid sequences deduced for an assess-
ment of PfHRP2 and PFHRP3 diversity, respectively. The remaining 156 pfhrp2 and 133 pfhrp3 PCR products 
were excluded from further analysis because the nucleotide sequences for these amplicons could not be obtained 
despite repeated attempts. PfHRP2 and PfHRP3 amino acid sequence diversity among Kenyan P. falciparum iso-
lates was characterised by differences in the frequency, occurrence and structural organisation of different amino 
acid repeat types.
PfHRP2 diversity. A total of 228 different PfHRP2 amino acid sequences were identified among 244 PfHRP2 
sequences deduced in this study. The size of PfHRP2 was between 206 and 317 amino acids. Overall, PfHRP2 
had a total of 20 to 37 amino acid repeat types per isolate. The organization of the amino acid repeat types in 
PfHRP2 was highly diverse. Thus, 94% (214/228) of PfHRP2 sequences occurred once only. The remainder (14) 
were shared among 30 isolates of which 12 sequences were identified in 2 isolates and 2/14 sequences occurred 
in 3 isolates.
Thirteen previously reported PfHRP2 amino acid repeat types were identified in P. falciparum isolates from 
Kenya as shown in Table 116. The frequency of these repeat types was similar among Western and Coastal Kenyan 
isolates. Table 2 shows the occurrence of PfHRP2 repeat types in this study. Repeat types 2 and 7 were identified 
in all isolates, whereas repeat types 1, 3, 5, 6, 8, 10 and 12 were observed in 80% to 99% of the isolates. Repeat 
type 4 (27%) occurred in a few isolates only. Repeat types 13 (8.2%), 14 (6.6%) and 19 (1.2%) were rare. All iso-
lates lacked repeat types 9 and 11. Repeat type 14 did not occur in Tiwi, Coastal Kenya, and repeat type 19 was 
identified in only three isolates (3%) from Busia, Western Kenya. Most of the PfHRP2 repeat types had a similar 
occurrence within and between Western and Coastal Kenya, except for four repeat types (Table 2). Type 6 was 
significantly more prevalent and type 10 was significantly less prevalent in Western than in Coastal Kenya. Type 
14 was significantly more prevalent in Msambweni than in Tiwi. Thirty-nine new PfHRP2 repeat types, which 
have not been reported previously, were identified at low frequencies with repeat type AHHAAH (5.7%) being 
the most common one (Table 3).
We classified P. falciparum isolates into groups A, B, I and C based on the product of the number of repeat type 
2 and type 7 (type 2 × type 7), as described in the methods section (PfHRP2 and PfHRP3 diversity), to determine 
their distribution on basis PfHRP2 diversity. Our study revealed that most of the isolates were in group B (type 
2 × type 7; ranges from 50 to 100) (Table 4). The occurrence of group A (type 2 × type 7; >100) was significantly 
higher in Mbita than in Busia and Nyando, Western Kenya. In the Coastal region, however, the occurrence of 
group C (type 2 × type 7; <43) was significantly higher in Tiwi than in Msambweni.
The structural organisation of the PfHRP2 repeat types was highly variable. Nevertheless, three characteristic 
features were observed. The repetitive region of most of the PfHRP2 sequences began with repeat type 1 in 96% to 
99% of the P. falciparum isolates, ended with type 12 in 85.5% to 96.8% of P. falciparum isolates and had a semi−
conserved PfHRP2 repeat type motif composed of repeat types 2, 3, 5, 7 and 8 in 50% (121/244) of the isolates as 
illustrated in Fig. 1a. Twenty−eight percent of the isolates shared parts of this motif composed of types 7, 8 and 2. 
These two motifs were not identified in 55 isolates.
PfHRP3 diversity. A total of 124 different PfHRP3 amino acid sequences were deduced from 267 pfhrp3 
(exon 2) nucleotide sequences obtained in this study. The size of PfHRP3 ranged from 160 to 247 amino acids, 
whereas the total number of amino acid repeat types per isolate ranged between 18 and 33 types. Repeat types 1, 4 
and 7 identified in PfHRP2 were also present in PfHRP3. The number of repeat types 16, 17 and 18 per isolates var-
ied most (Table 1). Apart from type 2, which occurred only in one isolate from Nyando, the other repeat types had 
an occurrence of ≥97%. We identified 20 new PfHRP3 repeat types that have not been reported previously at low 
frequencies (Table 3). The amino acid sequence SHHDG was the most common (9.7%) novel PfHRP3 repeat type.
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Structurally, PfHRP3 was more conserved than PfHRP2. Eighty-one out of 124 (65.3%) different PfHRP3 
sequences occurred only once, whereas 43/124 (34.7%) different PfHRP3 sequences were shared by 2–17 isolates 
each. In addition, the organisation of repeats was conserved between isolates as shown in Fig. 1b. A non-repetitive 
sequence was located between two PfHRP3 repetitive motifs.
PfHRP2 concentration in whole blood samples. PfHRP2 levels were measured in samples from 
96 uncomplicated malaria cases with a median parasite density of 21,400 parasites/µl (interquartile range, 
IQR: 7,781–34,180 parasites/µl) and a mean haemoglobin level of 10.48 g/dl (95% CI 10.13–10.82 g/dl). The 
Repeat types Repeat sequence PfHRP2 PfHRP3
Malaria-endemic region
OverallWestern Coastal
Type 1 AHHAHHVAD + + 0–6 0–9 0–9
0–4 1–3 0–4
Type 2 AHHAHHAAD + + 7–18 6–16 6–18
0–1 0 0
Type 3 AHHAHHAAY + − 0–3 0–3 0–3
Type 4 AHH + + 0–6 0–6 0–6
1 1 1
Type 5 AHHAHHASD + − 0–3 0–3 0–3
Type 6 AHHATD + − 0–8 0–6 0–8
Type 7 AHHAAD + + 2–12 1–12 1–12
0–1 1 0–1
Type 8 AHHAAY + − 0–3 0–3 0–3
Type 10 AHHAAAHHATD + − 0–3 0–3 0–3
Type 12 AHHAAAHHEAATH + − 0–1 0–1 0–1
Type 13 AHHASD + − 0–2 0–2 0–2
Type 14 AHHAHHATD + − 0–2 0–2 0–2
Type 15 AHHAHHAAN − + 0–1 0–1 0–1
Type 16 AHHAAN − + 6–18 9–15 6–18
Type 17 AHHDG − + 3–10 3–8 3–10
Type 18 AHHDD − + 1–4 1–3 1–4
Type 19 AHHAA + − 0–1 0 0–1
Type 20 SHHDD − + 1 1 1
Table 1. Comparison of the range of individual PfHRP2 and PfHRP3 repeat types in malaria-endemic sites of 
Kenya. The plus (+) and minus (−) signs show the presence or absence, respectively, of individual amino acid 
repeats in PfHRP2 and PfHRP3. The range of individual amino acid repeats in PfHRP3 is shown in bold.
Repeat 
types
Western Coastal Regional Total Overall
Nyando n 
(%)
Busia n 
(%)
Mbita n 
(%) p-valuea
Msambweni 
n (%)
Tiwi n 
(%) p-valuea
Western n 
(%)
Coastal n 
(%) p-valueb
Total n 
(%)
Type 1 30 (96.8) 116 (99.1) 24 (96.0) ns 37 (94.9) 32 (100) ns 170 (98.3) 69 (97.2) ns 239 (98.0)
Type 2 31 (100) 117 (100) 25 (100) ns 39 (100) 32 (100) ns 173 (100) 71 (100) ns 244 (100)
Type 3 29 (93.5) 109 (93.2) 21 (84) ns 33 (84.6) 29 (90.6) ns 159 (91.9) 62 (87.3) ns 221 (90.6)
Type 4 8 (25.8) 28 (23.9) 7 (28.0) ns 10 (25.6) 13 (40.6) ns 43 (24.9) 23 (32.4) ns 66 (27.0)
Type 5 25 (80.6) 91(77.8) 19 (76.0) ns 35 (89.7) 26 (81.3) ns 135 (78) 61 (85.9) ns 196 (80.3)
Type 6 31 (100) 116 (99.1) 25 (100) ns 32 (82.1) 32 (100) 0.014 172 (99.4) 64 (90.1) 0.001 236 (96.7)
Type 7 31 (100) 117 (100) 25 (100) ns 39 (100) 32 (100) ns 173 (100) 71 (100) ns 244 (100)
Type 8 30 (96.8) 111 (94.9) 24 (96.0) ns 38 (97.4) 31 (96.9) ns 165 (95.4) 69 (97.2) ns 234 (95.9)
Type 10 27 (87.1) 97 (82.9) 23 (92.0) ns 38 (97.4) 31 (96.9) ns 147 (85) 69 (97.2) 0.007 216 (88.5)
Type 12 30 (96.8) 100 (85.5) 24 (96.0) ns 36 (92.3) 29 (90.6) ns 154 (89) 65 (91.5) ns 219 (89.8)
Type 13 2 (6.5) 9 (7.7) 3 (12.0) ns 3 (7.7) 3 (9.4) ns 14 (8.1) 6 (8.5) ns 20 (8.2)
Type 14 1 (3.2) 13 (11.1) 2 (8.0) ns 8 (20.5) 0 0.007 16 (9.2) 8 (11.3) ns 24 (9.8)
Type 19 0 3 (2.6) 0 ns 0 0 ns 3 (1.7) 0 ns 3 (1.2)
Table 2. Comparison of the occurrence of individual PfHRP2 repeat types within and between two malaria-
endemic regions in Kenya. The 244 isolates analysed were distributed as follows; Nyando 31, Busia 117, 
Mbita 25, Msambweni 39 and Tiwi 32 isolates. The superscript letters show the p-values of comparison of the 
occurrence of repeat types within (a) and between (b) malaria-endemic regions in Kenya. Statistically significant 
difference (p < 0.05) shown in bold. ns: not significant.
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PfHRP2 PfHRP3
Repeat 
Types Known repeats Novel Repeats (%)
Repeat 
Type Known repeats Novel Repeats (%)
Type 1 AHHAHHVAD AHHAHHVAY 0.8 Type 1 AHHAHHVAD AHHAHHGAE 0.3
AHHAHHVPD 0.4 AHHSHHVAD 0.7
AHHTHHVAD 0.4 AHQAHHVAD 0.3
Type 2 AHHAHHAAD AHHADHAAD 0.4 AQHAHHVAD 0.3
AHHAHHAAH* 4.1 Type 7 AHHAAD AHHADD 0.3
AHHAHHADD 1.2 Type 15 AHHAHHAAN AHHAHHAPH 0.3
AHHAHHADH 0.4 Type 16 AHHAAN AHHAAH* 0.7
AHHAHHAPD 0.8 AHHADN 0.3
AHHAHHAPH 0.4 AHHAPH 0.3
Type 4 AHH AHQ 0.4 AHHASN* 1.5
ADH 0.4 AHHTAN 0.3
Type 5 AHHAHHASD AHHAPHASD 0.4 AHQADN* 0.3
AHHDHHASD 0.4 AYHASH 0.3
Type 6 AHHATD AHHATH 0.4 Type 17 AHHDG AHHDE 0.3
Type 7 AHHAAD AHHAPD 0.4 AHHDH 0.3
AHHAAH* 5.7 AHYDG 0.3
AHHADD* 2.0 PHHDG 0.7
AHHAHD 0.4 PHQDG 0.3
AHHAND 1.2 SHHDG 9.7
AHHANH 0.4 Type 18 AHHDD APHDD 0.3
Type 8 AHHAAY AHHADY 0.4
Type 10 AHHAAAHHATD AHHAAAHDAND 0.4
AHHAAAHHAND 0.8
AHHAAAHHATG 0.4
AHHAATHHATD 1.2
AHHAATHHATD 0.4
Type 12 AHHAAAHHEAATH ADHAAAHDDAATH 0.4
ADHAAAHHEAATH 0.4
AHHAAAHDDHATH 0.4
AHHAAAHDEAATH 0.8
AHHAAAHHEAAAH 0.8
AHHAAAHHEAASH 0.4
AHHAAAHHESATH 0.4
AHHAAAHHHAATH 0.4
AHHAAAHPEAATH 0.4
AHHAAPHHEAATH 0.4
AHHADAHHDAATH 0.4
Type 13 AHHASD AHHASH 0.4
Table 3. List of new PfHRP2 and PfHRP3 amino acid repeat types identified in Kenya. The asterisks (*) shows 
new repeat types with >1 copy per isolate. The single-letter amino acid code in bold shows the position where 
the novel repeat types differ from the known repeat types. % shows the occurrence of the novel repeat types.
PfHRP2 
groups
Western Coastal Regional total
p-valueb
Overall
Nyando n 
(%)
Busia n 
(%)
Mbita n 
(%) p-valuea
Msambweni 
n (%)
Tiwi n 
(%) p-valuea
Western n 
(%)
Coastal 
n (%)
Total n 
(%)
Group A 0 10 (8.5) 5 (20.0) 0.025 2 (5.1) 1 (3.1) ns 15 (8.7) 3 (4.2) ns 18 (7.4)
Group B 27 (87.1) 90 (76.9) 17 (68.0) ns 30 (76.9) 21 (65.8) ns 134 (77.5) 51 (71.8) ns 185 (75.8)
Group I 0 8 (6.8) 2 (8.0) ns 5 (12.8) 2 (6.3) ns 10 (5.7) 7 (9.9) ns 17 (7.0)
Group C 4 (12.9) 9 (7.7) 1 (4.0) ns 2 (5.1) 8 (25.8) 0.035 14 (8.1) 10 (14.1) ns 24 (9.8)
Table 4. Comparison of the occurrence of PfHRP2 groups (Baker model) within and between malaria-endemic 
regions of Kenya. Groups A, B, I and C constitute PfHRP2 sequence whose Baker repeat type 2 × type 7 number 
is >100, ranges from 50 to 100, ranges from 44 to 49 and <43, respectively. The superscript letters show the 
p-values of the comparison group occurrence within (a) and between (b) malaria-endemic regions of Kenya. 
Statistically significant difference (p < 0.05) shown in bold. ns: not significant.
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concentration of PfHRP2 in whole blood among the participants was highly variable. It ranged from 339.3 ng/ml 
to 13,766 ng/ml with a median of 2,470 ng/ml (IQR: 980.8 ng/ml–6,670 ng/ml). PfHRP2 levels did not correlate 
with parasitemia, the number of individual PfHRP2 repeat types per isolate and the product of the number of 
repeat types 2 and 7 per isolate (Fig. 2).
Discussion
PfHRP2 targeting RDTs are an important pillar of malaria control programmes and promote access to malaria 
diagnosis where microscopy is not available. Future use of these tests in malaria-endemic countries is threatened 
by the spread of isolates that do not express PfHRP218,24,25. Since most of the commercially available RDTs target 
PfHRP2 expressed solely by P. falciparum, analysis of pfhp2/3 genetic diversity is of public health importance.
We analysed the diversity of pfhrp2 and pfhrp3 among 400 isolates collected at five different time points (2007–
2016) in Coastal and Western Kenya. Our study shows that pfhrp2 and pfhrp3 deletion did not occur among these 
isolates. This is consistent with two previous reports16,17. In 2017, however, Beshir et al. published the first report 
of pfhrp2 deletion in Mbita, Kenya15. We analysed 58 samples collected from this area in 2007, seven years before 
Figure 1. Schematic diagram of the structural organisation of PfHRPs 2 and 3 amino acid repeat types in 
Kenya. (a) P. falciparum histidine-rich protein 2. (b) P. falciparum histidine-rich protein 3. *Semi-conserved 
amino acid repeat motif; **partial amino acid repeat motif.
Figure 2. Results of Spearman’s correlation analysis between PfHRP2 levels and three P. falciparum parameters. 
(a) PfHRP2 vs. Parasitemia. (b) PfHRP2 vs. Total number of PfHRP2 repeat types per isolate. (c) PfHRP2 vs. 
Product of the number of repeat types 2 and 7. Statistical significance set at p-value < 0.05.
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the Beshir et al. sample collection in 2014. Absence of pfhrp2/3 deletion in the present study strongly suggests that 
the reported pfhrp2 and pfhrp3 deletion may have occurred only recently in Mbita. It is important to note that the 
analysis of a small sample size in our study and the inclusion of symptomatic malaria cases may have influenced 
the results of this study. The latter is highly plausible considering that the Beshir et al. study analysed isolates 
obtained from asymptomatic malaria cases. Moreover, differences in the complexity of infection (COI) could have 
limited the detection of pfhrp2/3 deletion as reported recently26.
At the amino acid sequence level, the structural organisation of repeat types was highly diverse. Ninety−four 
percent of the different PfHRP2 sequences identified in this study occurred only once. Similar findings have been 
reported in other malaria-endemic countries with Peruvian isolates being the least diverse16,17. Nevertheless, sev-
eral characteristics were shared between isolates. Majority of the PfHRP2 sequences started with repeat type 1 and 
terminated with type 12, unlike in isolates from Senegal where type 12 was uncommon27. Similarly, 50% of the 
isolates had a previously described motif of repeat types 2, 3, 5, 7, 8, 2 and 7, which has been identified in 44% of P. 
falciparum isolates globally16. An additional 27% of our isolates had part of this motif (7, 8, 2 and 7), which is pre-
dominant in isolates from Madagascar28. The motif of types 2, 4, 5, 6, 7 and 8 found in Indian isolates was absent13.
In contrast to the diverse structural organisation described here, subtle differences were observed in the 
occurrence and number of PfHRP2 repeat types per isolate between and within Kenyan malaria-endemic sites. 
We found types 2 and 7 in all isolates, however, types 9 and 11 were completely absent in all isolates as reported 
elsewhere13,16,27–32. Type 4 was found in a few isolates (27%) and the rare types 13 and 14 were found in <8% of 
isolates27,29–31,33. Our data show for the first time the occurrence of type 19 (3 isolates) in Kenya. Other countries 
where type 19 was found are Uganda, Senegal, Mali and the Philippines16,30,33. The prevalence of the other repeat 
types identified were >80% consistent with earlier reports.
PfHRP3, on the other hand, showed lower variation than PfHRP2 in its structural organisation, occurrence 
and number of repeat types. This is reflected by the omnipresence of eight PfHRP3 repeat types identified previ-
ously17, the presence of a conserved repeat type organisation and a lower proportion (65%) of different PfHRP3 
repeat type profiles. The identification of type 2 in the PfHRP3 of one isolate from Nyando confirmed our previ-
ous observation of the occurrence of this repeat in one isolate from Busia, Western Kenya, during the evaluation 
of a malaria RDT34. This strengthens our earlier hypothesis that type 2 presence in PfHRP3 may have occurred 
recently among Kenyan P. falciparum isolates. Beyond the Kenyan borders, the presence of type 2 in PfHRP3 has 
been reported from India at a prevalence of 2.9%33.
Another characteristic feature of histidine-rich proteins 2 and 3 from Kenyan isolates was the presence of 
repeat types that have not been described previously. Here, we identified 59 new repeat types arising from replace-
ment of ≥1 amino acid of the previously described PfHRP2 and PfHRP3 repeat types. Majority of these new 
repeat types (39/59) were identified in PfHRP2, consistent with its higher diversity. A similar phenomenon was 
observed among isolates from the Chinese-Myanmar border where novel PfHRP2 repeat types originated from 
replacement of a single amino acid of eight amino acid repeats types, compared to the replacement ≥1 amino acid 
in 14 repeat types reported in this study31. Five additional repeats types (novel) have also been identified in Indian 
isolates33. Our study corroborates the existence of repeat types that are yet to be described and shows that they 
have a low prevalence. It also shows that there is a limited distribution of the new repeat types between different 
geographical regions. This is exemplified by the observation of the novel repeats types AHHAHHVAY (PfHRP2) 
and SHHDG (PfHRP3) among Kenyan isolates that were previously found in isolates from the China-Myanmar 
border and India, respectively31,33. Nevertheless, the new PfHRP2 repeat type AHHAAH (6%) and the new 
PfHRP3 repeat type SHHDG (10%) were most frequent in this study.
Currently it is of major importance in how far PfHRP2 diversity may affect malaria diagnoses based on the 
detection of PfHRP2. Baker et al. demonstrated, using a binary logistic regression model (Baker model), that the 
observed inter-study sensitivity variation of PfHRP2-based RDTs is linked to the product of the number of type 2 
and type 7 (type 2 × type 7), especially with parasite densities of ≤250 parasites/µl17. In 2010, Baker et al. showed 
that RDT sensitivity does not correlate with type 2 × type 7 of isolates from different geographical areas16. Studies 
by Kumar et al. (2012) and Wurtz et al. (2013) have, however, associated type 2 × type 7 below 43 (group C) with 
RDT false negativity and reduced limited of detection, respectively13,14. This study was not able investigate this 
relationship in Kenyan isolates owing to the lack of PfHRP2-based RDT testing of the samples analysed here. 
Nevertheless, we utilized PfHRP2 classification of isolates based on type 2 × type 7 to determine the distribution 
of Kenyan isolates on basis of PfHRP2 diversity17. Our data reveals that most of Kenyan isolates (76%) are in 
group B (type 2 × type 7; ranges from 50 to 100). This finding is congruent with studies from Madagascar (69%) 
and Senegal (71%)27,28 and is comparable to our recent observation of 71% group B isolates in a small size of 38 
samples34.
PfHRP2-specific monoclonal antibodies have been reported to also detect PfHRP3, a PfHRP2 homologue17,35. 
This cross-reactivity originates from the presence of repeat types 1, 2, 4 and 7, which are also found in PfHRP2. 
Consistent with this observation, we identified repeat types 1, 4 and 7 in PfPHP2 and PfHRP3 of Kenyan isolates 
apart from one isolate that exhibited these repeat types in addition to type 2. This implies that PfHRP3 may be 
useful in modulating the impact of PfHRP2 antigenic polymorphism in the context of malaria diagnosis using 
PfHRP2-based RDTs15,36,37. Whether cross-reactivity offers a diagnostic advantage remains to be validated due to 
the current lack of PfHRP3-specific monoclonal antibodies.
Along with genetic deletion and diversity of histidine-rich proteins 2 and 3, suboptimal antigen levels can con-
tribute to false negative results of RDTs38. We observed a significant variation of PfHRP2 concentrations among 
uncomplicated malaria cases from Busia County, Kenya. Furthermore, the level of PfHRP2 did not correlate with 
parasitemia or the number of PfHRP2 repeat types per isolate. While we could not assess RDT sensitivity directly, 
our findings suggest that repeat type is not likely to be associated with RDT sensitivity, as previously observed 
by Baker et al.16. A previous study demonstrated, in vitro, that PfHRP2 expression varies between strains, the 
erythrocytic stages of P. falciparum and the mature schizonts account for most of the PfHRP2 released39. This 
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presents a methodological challenge when investigating factors influencing PfHRP2 levels in the host. Additional 
confounding factors include PfHRP2 antibody cross-reaction with PfHRP3, PfHRP2 expression by gametocytes, 
slow antigen clearance and residual PfHRP2 from previous infections6,40–42. Nevertheless, the potential impact of 
PfHRP2 levels on sensitivity needs also to be considered during the evaluation of RDTs.
Taken together, this study shows extensive diversity of Plasmodium falciparum histidine-rich proteins 2 and 3 
in Kenyan isolates. It also highlights the existence of additional amino acid repeat types which extends PfHRP2 
and PfHPR3 antigenic variability. Information from this study will be useful to understand the performance of 
PfHRP2-detecting RDTs in this setting.
Methods
Study sites and sample selection. Four hundred P. falciparum isolates collected from symptomatic 
malaria cases in the frame of antimalarial drug efficacy trials conducted between 2007 and 2016, in malar-
ia-endemic sites situated in Western (Mbita 2007, Nyando 2015 and Busia 2016) and Coastal (Tiwi 2008 and 
Msambweni 2013) Kenya were analysed in this study (Fig. 3). An inclusion criterion of >2,000 to 200,000 para-
sites/µl by microscopy was used in these studies. Samples were obtained before antimalarial drug administration 
and stored as dried blood spots (DBS) on filter papers, except isolates collected in Busia (whole blood in EDTA). 
Samples were included in the study after P. falciparum infection was confirmed using a P. falciparum-specific 18 S 
ribosomal RNA (rRNA) nested PCR.
Ethical Statement. The study was approved by the Scientific & Ethics Review Unit (SERU) of Kenya 
Medical Research Institute (KEMRI) Nairobi (KEMRI/SERU/0152/3250) and written informed consent was 
obtained from the parents/guardians of all children and from adult participants. All experiments were performed 
in accordance with relevant guidelines and regulations.
Molecular analysis. Genomic DNA was extracted using QIAamp DNA mini kit (Qiagen, Hilden, Germany) 
following the manufacturer’s instructions. Individual PCRs targeting P. falciparum 18S rRNA, pfhrp2 (exon 2) and 
pfhrp3 (exon 2) were performed as described previously (Table S1)17,43. Briefly, 1 µl of DNA template was added 
into a master mix containing 1 × PCR buffer (Qiagen, Hilden, Germany), 200 µM of each dNTP, 1 unit of Qiagen 
Taq DNA polymerase (Qiagen, Hilden, Germany), and 100 nM of each primer in a total volume of 20 µl. Genomic 
DNA of three P. falciparum strains was used as controls, namely 3D7 (pfhrp2+ and pfhrp3+), Dd2 (pfhrp2− and 
pfhrp3+) and Hb3 (pfhrp2+ and pfhrp3−).
pfhrp2 and pfhrp3 PCR products were purified using SephadexTM G-50 fine DNA grade (GE Healthcare, 
Buckinghamshire, UK) and sequenced using the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied 
Biosystems, CA, USA) according to the manufacturer’s instructions. PCR products were sequenced in the forward 
and reverse direction. DNA sequence chromatograms were visually inspected to resolve discordant base-calling. 
BioEdit (http://www.mbio.ncsu.edu/BioEdit/bioedit.html) was used to assemble the nucleic acid sequences using 
Figure 3. Map of Kenya showing the geographical location of the study sites. MSW is an abbreviation for 
Msambweni. The number of P. falciparum isolates recruited per study site shown in parentheses.
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P. falciparum 3D7 pfhrp2 (PF3D7_0831800) and pfhrp3 (PF3D7_1372200) DNA sequences as the references as 
well as deduce amino acid sequences of PfHRP2 and PfHRP3.
PfHRP2 and PfHRP3 diversity. The diversity of PfHRP2 and PfHRP3 was described based on the fre-
quency, occurrence and organisation of histidine-rich protein repeat types (numerically coded as repeat types 1 
to 24) as described by Baker et al.16,17. The product of the number of PfHRP2 repeat types 2 and 7 (type 2 × type 7) 
was used to classify P. falciparum isolates into four groups, namely group A (very sensitive), group B (sensitive), 
group I (borderline) and group C (non-sensitive) when the number of type 2 × type 7 was above 100, ranged from 
50 to 100, ranged from 44 to 49, and less than 43, respectively. This was conducted to determine the distribution 
of P. falciparum isolates based on PfHRP2 diversity.
PfHRP2 quantification by enzyme-linked immunosorbent assay (ELISA). The measurement 
of PfHRP2 levels in whole blood samples of uncomplicated malaria cases from Busia County was conducted 
using a commercial sandwich ELISA kit (Malaria Ag CelisaTM, Cellabs, Sydney, Australia) in accordance with 
the manufacturer’s instructions. The optical density (OD) was measured at 450 nm in a PHOmo reader (Autobio 
Diagnostics Co. Ltd, Zhengzhou, China). The OD cut-off level was set by calculating the mean OD + 3 SD of three 
negative controls included in each ELISA run. OD above and below the cut-off was regarded to be positive and 
negative, respectively. PfHRP2 concentration was calculated using a standard curve prepared using serial dilu-
tions (1:1) of recombinant PfHRP2 in phosphate buffered saline (PBS).
Data Analysis. Chi-square and Fisher’s exact tests were used to compare the occurrence of amino acid repeat 
types between and within malaria-endemic sites. Kruskal Wallis and Mann-Whitney U tests were applied for 
analysis of non-parametric data. Significance was observed at a p-value < 0.05.
Data Availability
Data analysed in this publication are available from the corresponding author on reasonable request. Plasmodium 
falciparum histidine-rich proteins 2 and 3 nucleic acid sequences are available in GenBank (pfhrp2: accession 
numbers MH230283 - MH230526; pfhrp3: accession numbers: MH230527 - MH230790).
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Summary Kenya has, in the last decade, made tremendous progress in the fight against malaria. Nevertheless,
continued surveillance of the genetic diversity and population structure of Plasmodium falciparum is
required to refine malaria control and to adapt and improve elimination strategies. Twelve neutral
microsatellite loci were genotyped in 201 P. falciparum isolates obtained from the Kenyan–Ugandan
border (Busia) and from two inland malaria-endemic sites situated in western (Nyando) and coastal
(Msambweni) Kenya. Analyses were done to assess the genetic diversity (allelic richness and expected
heterozygosity, [He]), multilocus linkage disequilibrium (I
A
S ) and population structure. A similarly
high degree of genetic diversity was observed among the three parasite populations surveyed (mean
He = 0.76; P > 0.05). Except in Msambweni, random association of microsatellite loci was observed,
indicating high parasite out-breeding. Low to moderate genetic structure (FST = 0.022–0.076;
P < 0.0001) was observed with only 5% variance in allele frequencies observed among the
populations. This study shows that the genetic diversity of P. falciparum populations at the Kenyan–
Ugandan border is comparable to the parasite populations from inland Kenya. In addition, high
genetic diversity, panmixia and weak population structure in this study highlight the fitness of
Kenyan P. falciparum populations to successfully withstand malaria control interventions.
keywords Plasmodium falciparum, microsatellites, genetic diversity, population structure, malaria,
Kenya
Introduction
Malaria is a major public health problem accounting for
about 219 million morbidities and 435 000 mortalities
reported in 2017 globally [1]. Ninety per cent of the dis-
ease burden occurs in sub-Saharan Africa, in particular in
children below 5 years. In Kenya, malaria is the second
leading cause of morbidity and mortality [2]. The contin-
uous fight against malaria has led to a remarkable reduc-
tion in disease incidence and fatalities in recent years
[3–5]. These achievements are largely attributed to the
improved malaria control policy, including widespread
use of artemisinin-based combination therapies (ACTs)
and the scale-up of mosquito vector control [3–5].
Malaria treatment guidelines have undergone numer-
ous changes in the last three decades. In the late 1990s,
sulfadoxine–pyrimethamine (SP) replaced chloroquine
(CQ) as first-line treatment for uncomplicated P. falci-
parum malaria in Kenya, due to treatment failure and
the advent of CQ resistance [6]. SP efficacy was short-
lived, also due to the rapid development of drug resis-
tance. Since 2006, artemether–lumefantrine (AL) has
been the antimalarial drug of choice in Kenya [7, 8]
and in other countries of sub-Saharan Africa. The
changes in drug policy have elicited notable changes in
P. falciparum population genetics. For instance, the fre-
quency of non-synonymous mutations in P. falciparum0s
kelch 13 gene has increased, even though these muta-
tions are not associated with delayed parasite clearance
[9], whereas the frequency of distinct single-nucleotide
polymorphisms conferring resistance to CQ and SP has
declined after the withdrawal of these drugs in 1999
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and 2006 respectively [10, 11]. Continued SP use in
intermittent preventive treatment in pregnancy (IPTp)
has recently been linked to the resurgence of SP resis-
tance markers in Kenya [10, 11]. The shift from CQ
and SP to AL in uncomplicated malaria treatment has
increased the genetic diversity of the Kenyan P. falci-
parum population because of the reduced drug selection
pressure [12].
Plasmodium falciparum genetic diversity was expected
to decline with malaria transmission and disease preva-
lence reduction. However, this has not been the case
despite the intensified deployment of vector control
measures such as use of insecticide-treated nets (ITNs)
and insecticide residual spraying (IRS). Analyses con-
ducted 5 and 10 years after ITN introduction showed
no change in the genetic diversity and population struc-
ture of P. falciparum populations from inland Kenya
[13, 14]. Increasing asymptomatic malaria prevalence
with higher gametocytaemias [15], mosquito vector
resistance to pyrethroids [16], changing mosquito biting
behaviour [17, 18] and high gene flow [19–21] are
some of the prominent factors informing the resilience
of P. falciparum genetic variability and population
structure.
Plasmodium falciparum genetic factors are also depen-
dent on transmission intensity. P. falciparum populations
from low malaria transmission settings such as South
America and Southeast Asia are characterised by low
genetic diversity with strong linkage disequilibrium (LD)
and defined structures of parasite populations [22]. In
sub-Saharan high transmission regions, P. falciparum
strains exhibit high genetic diversity, non-defined popula-
tion structures and weak LD. Nevertheless, parasite
inbreeding and subtle population fragmentation have
been observed in a few high transmission areas despite
the prevailing high genetic diversity, in particular in Sene-
gal, Niger, Republic of Djibouti, Zimbabwe, Republic of
Congo and Kenya [20, 22–24].
The level of genetic diversity and panmixia contributes
to the fitness of P. falciparum to counter malaria control
interventions such as candidate malaria vaccines [25] as
well as the emergence and dispersal of antimalarial
drug-resistant parasites. Insight into the genetic diversity
and population structure of P. falciparum populations is
vital to refine and effectively implement malaria control
and elimination strategies. This study describes the
genetic diversity and population structure of P. falci-
parum populations from a distinct region of the
Kenyan–Ugandan border (Busia) in comparison to P. fal-
ciparum populations from two inland areas in Kenya,
namely Msambweni in coastal Kenya and Nyando in
western Kenya.
Methods
Ethical considerations
The study was approved by the Scientific & Ethics
Review Unit (SERU) of Kenya Medical Research Institute
(KEMRI) Nairobi (KEMRI/SERU/0152/3250 and
SSC2276). Written informed consent was obtained from
the parents/guardians of all children. All experiments
were performed in accordance with good laboratory
practice guidelines.
Study sites and study samples
The study was conducted in malaria-endemic areas situ-
ated in western (Busia and Nyando) and coastal
(Msambweni) Kenya regions (Figure 1). Busia is located
in Busia County and borders Uganda; Nyando is located
in Kisumu County and Msambweni in Kwale county.
According to the national population census of 2009,
the population of Busia is 743 946 of Kisumu 968 909
and of Kwale 649 931 people [26]. Agriculture and fish-
ing are the main economic activities of these counties
owing to their proximity to Lake Victoria (Busia and
Kisumu Counties) and the Indian Ocean (Kwale
County).
Malaria transmission is perennial in the three study
areas with peak incidences shortly after the rainy seasons
(March to June and October to November). The preva-
lence of malaria in western Kenya ranges from 20% to
40% [27], whereas in the coastal region, it ranges
between 5% and 20% [28]. Most of the malaria cases
are due to P. falciparum infection. Co-infections of
P. falciparum and other Plasmodium species (P. malariae
and/or P. ovale) occur as well [29]. P. vivax is not pre-
sent. Three Anopheles mosquito vectors transmit malaria
in Kenya sympatrically; these include A. gambiae sensu
stricto, A. arabiensis and A. Funestus [30]. In the coastal
region, however, A. merus is an important secondary vec-
tor for malaria transmission [30].
Two hundred and one P. falciparum isolates obtained
from febrile children visiting health facilities in 2013
(Msambweni), 2015 (Nyando) and 2016 (Busia) were
analysed in this study (Figure 1). Patients from all study
sites were recruited during the rainy season. Para-
sitaemias ranged from >2000 to 200 000 parasites/ll as
assessed by microscopy. Genomic DNA was extracted
from dried blood spots on filter papers, except for Busia
(EDTA whole blood), using the QIAamp DNA mini kit
(Qiagen, Hilden, Germany) in accordance with the manu-
facturer’s instructions. A PCR method targeting the
P. falciparum 18S ribosomal RNA (rRNA) gene was
2 © 2019 John Wiley & Sons Ltd
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performed to confirm P. falciparum positivity as
described previously [31].
Plasmodium falciparum microsatellite loci genotyping
Twelve neutral microsatellite (MS) loci were used to
genotype P. falciparum isolates using a hemi-nested PCR
method described previously [32, 33]. The MS loci
included Poly-a (Chromosome, Chr, 4), TA81(Chr 5),
TA42 (Chr 5), TA87 (Chr 6), TA1 (Chr 6), TA109 (Chr
6), TA40 (Chr 10), 2490 (Chr 10), ARA2 (Chr 11),
PfG377 (Chr 12), PfPK2 (Chr 12) and TA60 (Chr 13).
From each sample, FAM, HEX and PET-labelled PCR
products were pooled together with GeneScanTM 500 Liz
size standard (Applied Biosystems, Foster City, CA, USA)
for capillary electrophoresis by the 3130xl Genetic Ana-
lyzer (Applied Biosystems) platform. The Peak ScannerTM
software version 1.0 (Applied Biosystems) was used to
visualise the electropherograms and automatically deter-
mine MS allele lengths relative to the GeneScanTM 500
Liz size standard. MS alleles per locus were scored if the
electropherogram peak height was ≥ 200 relative fluores-
cent units (RFU). Where more than one peak was
observed per MS locus, only the minor peak(s)
with ≥ 30% height of the predominant allele peak was/
were scored as additional allele(s). P. falciparum strain
3D7 genomic DNA and PCR grade water were used as a
positive and negative controls, respectively, for each run.
Data analysis
As the asexual stages of P. falciparum are haploid, the
number of multiple P. falciparum parasite strains in a
given individual was determined by the number of alleles
he/she carries among the investigated MS loci [32]. In
brief, a single or monoclonal infection is defined by the
observation of a single allele across all MS loci, whereas
multiple or polyclonal infections are defined by the obser-
vation of > 1 allele in at least one MS locus. The MS
locus with the highest number of alleles was used to
determine the number of multiple infections of a sample.
Kruskal–Wallis tests were applied to compare the mean
number of infections between study sites. Chi-square tests
were used to compare the proportion of multiple infec-
tions between study sites.
ARLEQUIN software version 3.5.2.2 (http://cmpg.uni
be.ch/software/arlequin35/) was used to analyse the
genetic diversity and population structure of Kenyan
P. falciparum isolates using the predominant alleles.
Genetic diversity was estimated by the allele frequencies,
number of alleles per MS locus (A), allelic richness (AR)
and the expected heterozygosity (He). Since A is
Uganda
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Figure 1 Map of Kenya showing study
sites. The sample size of each study site is
shown in parentheses. Black lines: country
borders, blue lines: rivers, star: the capital
city of Kenya.
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dependent on the sample size, AR was calculated using
the hierfstat package of the R software, based on the
smallest sample size, to normalise data. He is the proba-
bility that any two MS locus alleles observed in a popula-
tion are from different P. falciparum isolates. He was
determined by using the formula He ¼ nn 1 1
P
pi2
 
where pi was the frequency of the different alleles of a
given MS locus and n was the number of samples. The
non-random association of MS loci was estimated by the
multilocus linkage disequilibrium (LD). Multilocus LD
was determined by the index of association (IAS ) using
LIAN software, http://guanine.evolbio.mpg.de/cgi-bin/lia
n/lian.cgi.pl/query [34]. The paired Wright’s fixation
index (FST) and analyses of molecular variance
(AMOVA) were used to assess the population structure
of Kenyan P. falciparum isolates. The sum of genetic
variability between parasite populations was classified
and interpreted as follows: low differentiation, (FST value:
0–0.05), moderate differentiation (FST value: >0.05–
0.15), great differentiation (FST value: >0.15–0.25) and
very great differentiation (FST value: >0.25) [35]. Nei’s
genetic distance was used to assess the genetic relatedness
among populations. Significant differences were observed
at P-values < 0.05.
Results
Plasmodium falciparum genetic diversity
A total of 201 P. falciparum isolates were genotyped
using 12 neutral microsatellite (MS) loci. High allelic
polymorphism was observed with an overall mean of
10.14  1.07 alleles (Table 1). The total number of dif-
ferent alleles circulating at the various study sites did not
differ significantly. Furthermore, the difference between
the total number of different alleles and the mean allelic
richness did not reach statistical significance. This showed
that the sample size difference among study sites did not
influence the determination of allelic polymorphism. On
average, the MS locus TA40 had the highest number of
alleles (17.33), while loci PfG377 and 2490 were the
least polymorphic ones.
The genetic diversity of Kenyan P. falciparum isolates
was estimated by calculating the expected heterozygosity
(He) based on the allele frequencies of the predominant
alleles as described in the Methods section. The overall
He ranged from 0.45 (TA42) to 0.90 (TA40) and the
mean He was 0.76 (Table 1). The mean He of individual
study sites was not statistically different. Poly-a had the
highest He (0.92 in Busia) whereas 2490 and PfG377 in
Busia, as well as TA42 in Nyando, had the lowest He
(0.4). Figure 2a,b show the distribution and frequency of
alleles of the 12 MS loci. A few alleles were observed to
be predominant in at least one study site compared to the
others. Since the blood stages of P. falciparum are hap-
loid, we used the MS locus with the highest number of
alleles per sample to determine the number of infections
per sample and calculated the mean number of infections
as well as the proportion of samples with polyclonal
infections as described in the Methods section. The over-
all mean of the number of infections was 1.8 (95% CI:
1.6–1.8) and the overall proportion of polyclonal
Table 1 Genetic diversity of Plasmodium falciparum isolates from western (Busia and Nyando) and coastal (Msambweni) Kenya
Loci
A(AR) He Mean
Busia Nyando Msambweni Busia Nyando Msambweni A AR He
Poly-a 18 (18) 18 (13.35) 11 (10.39) 0.92 0.88 0.85 15.67 13.91 0.88
PfPK2 14 (10) 10 (10.22) 13 (12.22) 0.87 0.73 0.90 12.33 10.81 0.83
TA81 10 (10) 10 (8.04) 8 (7.62) 0.85 0.87 0.80 9.33 8.55 0.84
ARAII 11 (9) 9 (8.52) 8 (7.82) 0.81 0.82 0.86 9.33 8.45 0.83
TA87 13 (10) 10 (10.62) 10 (9.77) 0.88 0.87 0.88 11 10.13 0.87
TA40 23 (18) 18 (14.53) 11 (10.47) 0.89 0.91 0.89 17.33 14.33 0.90
TA42 7 (7) 7 (5.24) 7 (6.42) 0.47 0.41 0.47 7 6.22 0.45
2490 5 (6) 6 (3.54) 6 (5.77) 0.42 0.58 0.67 5.67 5.14 0.56
TA1 13 (13) 13 (10.28) 9 (8.79) 0.86 0.87 0.87 11.67 10.69 0.87
TA60 10 (6) 6 (8) 7 (6.65) 0.80 0.83 0.78 7.67 6.88 0.80
TA109 13 (7) 7 (8.32) 8 (7.6) 0.81 0.78 0.81 9.33 7.64 0.80
PfG377 6 (5) 5 (4.5) 5 (4.5) 0.43 0.57 0.54 5.33 4.77 0.51
Mean 12 (10) 10 (8.77) 9 (8.19) 0.75 0.76 0.78 10.14 8.96 0.76
SEM 1.5 (1.3) 1.27 (0.95) 0.67 (0.63) 0.056 0.045 0.041 1.07 0.90 0.046
A, number of alleles; AR, allelic richness; He, unbiased expected heterozygosity; SEM, standard error of mean, P-value > 0.05.
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infections was 51%. The mean of the number of infec-
tions and proportion of polyclonal infections was similar
among the study sites (P > 0.05). The mean of the num-
ber of infections among the samples from Nyando, Busia
and Msambweni was 1.6 (95% CI 1.3–1.9), 1.9 (95% CI
1.7–2.1) and 1.6 (95% CI 1.3–1.8) respectively. 45% of
samples from Nyando, 56% from Busia and 43% from
Msambweni had P. falciparum polyclonal infections.
Multilocus index of association analysis was performed
to assess the non-random association of all MS loci in
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the individual study sites. Statistical significance of link-
age disequilibria (LD) was tested using 10 000 Monte
Carlo simulations. The LD ranged from 0 in Busia to
0.04 in Msambweni. Significant multilocus LD was only
observed in Msambweni (Table 2). This resulted from
the repeated occurrence of four MS haplotypes. Three
MS haplotypes were shared by two isolates (4%) each,
whereas the remaining haplotype was shared by three
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isolates (6%). There were no matching MS haplotypes in
Busia and Nyando, indicating that these parasite popula-
tions are panmictic.
Genetic structure analyses performed by paired
Wright’s fixation index (FST) showed a significantly low
genetic differentiation in Busia vs. Msambweni
(FST = 0.022; P < 0.0001) and significant moderate
genetic differentiation in Busia vs. Nyando (FST = 0.076;
P < 0.0001) as well as in Nyando vs. Msambweni
(FST = 0.079; P < 0.0001). This shows that there were
differences in the frequency of alleles among the study
sites. Analysis of molecular variance (AMOVA) also
demonstrated significant genetic structuring of Kenya
P. falciparum isolates (P = 0.01). Overall, 95% of the
variance in allele frequencies observed was within popu-
lations, whereas 5% of the variance was observed across
populations (Table 3). The highest allele frequency vari-
ance (8%) among paired study sites was observed in
Busia vs. Nyando and Nyando vs. Msambweni, and the
lowest allele frequency variance (2%) occurred in Busia
vs. Msambweni (Table 4), indicating that the Kenyan
P. falciparum populations studied are closely related. A
short Nei’s genetic distance and a high gene flow (num-
ber of migrants [Nm]) determined here support these
findings. The Nei’s genetic distance between Busia and
Nyando was 0.294, 0.072 between Busia and Msamb-
weni and 0.34 between Nyando and Msambweni. The
overall Nm was 9.08 (Table 3). Interestingly, the Nm
between Busia and Msambweni was 3.7-fold higher than
between Busia and Nyando as well as between Nyando
and Msambweni (Table 4).
Table 2 Multilocus linkage disequilibrium in Plasmodium falci-
parum isolates from Kenya
Test factor Busia Nyando Msambweni
VD 1.90 2.05 2.64
VE 1.84 1.91 1.86
IAS 0.00 0.01 0.04
P-value 0.19 0.196 0.0001
Statistical significance at P-value < 0.05. IAS , index of association
calculated by Monte Carlo simulations at 10 000 per mutations
under the null hypothesis VD = VE; VD, observed variance; VE,
expected variance.
Table 3 Analysis of molecular variance in Kenyan Plasmodium falciparum population (Busia, Nyando and Msambweni)
Source of variation df Sum of squares Mean squares Estimated variance Percentage of variance (%) Nm
Among Population 2 37.94 18.97 0.25 5
Among individual 198 900.83 4.55 4.55 95 9.08
Within individual 201 0.00 0.00 0.00 0
Total 401 938.77 4.80 100
df, degrees of freedom; Nm, number of migrants; P-value = 0.01.
Table 4 Analysis of molecular variance in paired Plasmodium falciparum populations from Kenya
Populations Source of variation df
Sum of
squares
Mean
squares
Estimated
variance
Percentage of
variance (%) Nm
Busia and Nyando Among population 1 25.97 25.97 0.37 8
Among individual 153 691.15 4.52 4.52 92 6.04
Within individual 155 0 0.00 0.00 0
Total 309 717.12 4.89 100
Busia and Msambweni Among population 1 11.26 11.26 0.10 2
Among individual 161 731.8 4.55 4.55 98 22.35
Within individual 163 0 0 0 0
Total 325 743.06 4.65 100
Nyando and Msambweni Among population 1 21.03 21.03 0.39 8
Among individual 82 378.7 4.62 4.62 92 5.86
Within individual 84 0 0.00 0 0
Total 167 399.73 5.01 100
df, degrees of freedom; Nm, number of migrants; P-value = 0.01.
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Discussion
Malaria control strategies have changed tremendously
over the last three decades with the sole aim of reducing
the disease burden and safeguard gains, particularly in
sub-Saharan Africa where 90% of the global disease bur-
den occurs [30, 36]. The introduction and/or withdrawal
of malaria interventions have shaped P. falciparum
genetic factors. Insight into the genetic diversity and pop-
ulation structure of P. falciparum populations is vital for
refinement of malaria control and elimination strategies.
This study describes the genetic diversity and population
structure of P. falciparum in the Kenyan–Ugandan border
region (Busia, Busia County) in comparison to two inland
malaria-endemic sites of Kenya, Nyando (western Kenya)
and Msambweni (coastal Kenya).
Unexpectedly, we observed a lower proportion of poly-
clonal infections (51%) than previously reported in west-
ern Kenya. In 2018, Zhong et al. reported the prevalence
of polyclonal infections to be 75% in western Kenya
[37]. This was a slight reduction from the ≥ 80% preva-
lence reported by previous studies [13, 14, 19, 38]. Since
the prevalence of polyclonal infections is proxies of
malaria transmission, our findings suggest that malaria
transmission intensity has decreased in line with the
lower malaria prevalence in Kenya over the last three
decades [4]. However, this trend has not been observed
in the genetic diversity of the Kenyan P. falciparum pop-
ulation as exemplified in the present and in previous stud-
ies [13, 14, 19, 20, 38].
High P. falciparum genetic diversity has remained
unchanged in Kenya even after the introduction of artemi-
sinin-based combination therapy (ACT) and insecticide-
treated nets (ITN) [12–14]. In fact, the parasite genetic
diversity increased after ACTs were introduced [12].
Explanations for the persisting high genetic diversity are
the increasing number of asymptomatic malaria cases with
higher gametocytaemias, vector resistance against pyre-
throids which sustain transmission and the removal of anti-
malarial drug selection pressure following the replacement
of the less effective sulphadoxine–pyrimethamine in 2006
by the highly efficacious ACT [8, 12, 15, 16, 39, 40]. It is
also worth noting that the P. falciparum genetic diversity
reported here is similar to the genetic diversity of parasite
populations from other countries in sub-Saharan Africa
[22, 41], and it is higher than the genetic diversity of popu-
lations from low malaria-endemic settings in the
Pacific Region, Southeast Asia and South America
[22, 42–46].
Multilocus linkage disequilibrium (LD) analysis revealed
that P. falciparum populations in the Kenyan–Ugandan
border region and in Nyando are panmictic. This was
demonstrated by the lack of a significant index of associa-
tion (IAS ). In contrast, a significant I
A
S was observed in the
P. falciparum population from Msambweni with the
repeated occurrence of four MS haplotypes. This indicates
inbreeding in Msambweni and respective absence at the
Kenyan–Ugandan border and in Nyando. The level of mul-
tilocus non-random association in this study is lower than
previously reported in areas with intense transmission,
including Kenya [13, 14, 20, 22, 38]. The recent increase
(2011–2014) and subsequent decline (from 2015 on) of
malaria prevalence are likely to have altered the frequency
of minor alleles [4, 5], thus contributing to the lower LD
observed here. This is demonstrated by significant multilo-
cus LD in Asembo, western Kenya before deployment of
ITNs in 1996, followed by non-significant and significant
multilocus LDs in 2001 and 2007, respectively [13, 14].
The lower parasite prevalence in coastal (10–29%) and
western (≥30%) Kenya offers an alternative explanation
for the observed significant multilocus LD in Msambweni,
which was not seen in Busia and Nyando [4]. Apparently,
parasite inbreeding increases with a reduction transmission
[22].
The distance from Busia to Nyando is 163 km, and
from Busia to Msambweni, it is 987 km. However, our
data show that the parasite populations from these areas
are not isolated as previously described in Africa [22].
This becomes apparent by low to moderate genetic differ-
entiation and Nei’s genetic distance of parasite popula-
tions (Busia and Msambweni) separated by the longest
geographical distance. These results are also supported by
the low allele frequency variance (2%) in Busia vs.
Msambweni compared to 8% in both Busia vs. Nyando
and Nyando vs. Msambweni. In 2016, Ingasia et al.
reported similar findings in Kenyan P. falciparum popula-
tions separated by a similar geographical distance
(1000 km) as populations from Busia and Msambweni
which have a low genetic differentiation (FST = 0.027;
P < 0.0001) [20]. Busia is a socio-economically impor-
tant gateway to Uganda, a landlocked country. It
accounts for most of human travel between Kenya and
Uganda. Therefore, parasite migration via humans is the
likely reason for the limited genetic structure observed
here [20, 47]. The high parasite migration (Nm > 3) in
this study shows that there are limited barriers to hinder
genetic flow, particularly between the Kenyan–Ugandan
border region and Msambweni. Studies conducted in the
islands of Lake Victoria and Vanuatu demonstrate
human-mediated P. falciparum dispersal and gene flow
[21, 48]. The existence of high P. falciparum effective
population sizes in sub-Saharan Africa offers an addi-
tional explanation for the weak parasite population struc-
ture observed in this study [22].
8 © 2019 John Wiley & Sons Ltd
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In conclusion, this study shows that the genetic
diversity of P. falciparum populations in the Kenyan–
Ugandan border area and inland Kenya is similar. The
high panmixia and limited genetic population structure
highlight the genetic fitness of Kenyan P. falciparum
populations to counter the impact of current malaria
control interventions. Therefore, continued surveillance
of P. falciparum genetics and prompt refinement of
malaria control and elimination strategies is
needed to accelerate the realisation of a malaria-free
Kenya.
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3. DISCUSSION 
Recent stagnation of malaria reduction has heightened discussions on the approach 
and efficacy of current malaria control strategies as well as P. falciparum genetic 
diversity in an effort to refine and adapt malaria control/ elimination programmes. This 
dissertation describes the diagnostic performance of PfHRP2/pLDH−based rapid 
diagnostic test (RDT) and genetic diversity of P. falciparum populations in Kenya. 
 
3.1. Comparative evaluation of CarestartTM PfHRP2/pLDH (Pf) RDT  
The CarestartTM PfHRP2/pLDH (Pf) RDT is one of the RDTs currently deployed by the 
national malaria control programme of Kenya to promote testing and prompt treatment 
of confirmed cases of malaria with antimalarial drugs, especially with artemisinin-
based combined therapies. The first Chapter of my dissertation documents that 
CarestartTM has acceptable diagnostic performance in Kenya and in congruence with 
previous studies (Wanja et al., 2016, Osanjo et al., 2017, Adu-Gyasi et al., 2018). 
However, high false positive rate and low positive predictive values were observed. 
This could have been caused by the detection of persisting PfHRP2 after parasite 
clearance. On average, it takes 35 to 45 days for a patient to become negative after 
parasite clearance (Grandesso et al., 2016, Dalrymple et al., 2018). RDT false 
positives may also be attributed to PfHRP2 from P. falciparum sub−microscopic 
infections and/or gametocytes, the sexual stages of Plasmodium parasites. The 
consequences of RDT false positivity include over prescription of antimalarial drug, 
overestimation of malaria burden and impaired diagnosis of the cause(s) of febrile 
illnesses. Even though simultaneous RDT detection of PfHRP2 and pLDH could help 
avert this bottleneck as well as discern current and convalescent infections, PfHRP2− 
and PfHRP2/pLDH−based RDTs have comparable false positive rate (Adu-Gyasi et 
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al., 2018). RDTs targeting PfHRP2 are preferred to pLDH−based RDTs because of 
superior sensitivity and thermal stability (Li et al., 2017, Chiodini et al., 2007). 
 
In our investigations, microscopy, the gold standard for malaria diagnosis, had a 
limited of detection (LOD) of 80 parasites/µl. The LOD by microscopy may have 
influenced the sensitivity of CarestartTM RDT in the present study (Wanja et al., 2016). 
This is likely owing to the plausible occurrence of sub−microscopic P. falciparum 
infections with detectable PfHRP2 (Bell et al., 2005). In fact, we identified seven RDT 
and nested PCR (nPCR) positive cases missed by microscopy supporting this 
possibility and reiterating that microscopy is an imperfect gold standard (Kattenberg 
et al., 2011). The evaluation of CarestartTM with nested PCR as the reference method 
showed minimal changes in the RDT sensitivity and specificity. This is inconsistent 
with previous studies, thereby implying nested PCR performance in our study was 
comparable to microscopy (Swarthout et al., 2007, Wanja et al., 2016). Nevertheless, 
high negative predictive value and low negative likelihood ratio clearly demonstrate 
that negative CarestartTM RDT results can be used to rule out P. falciparum infections 
with sufficient confidence (Osanjo et al., 2017, Wanja et al., 2016, Singh et al., 2010).  
 
Of note, seven falciparum malaria cases with parasitemias ranging from 320 to 680 
parasites/µl were not detected by Carestart PfHRP2/pLDH RDT. Detection of P. 
falciparum infections with similar parasitemias in this study suggests that RDT false 
negativity could have been caused by other factors other than low parasitemia. 
Parasite genetics has been identified as a key factor that may alter RDT sensitivity, 
for instance, PfHRP2 gene deletion or diversity (Baker et al., 2005, Gamboa et al., 
2010). The relationship between PfHRP2 diversity and RDT false negativity could not 
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be investigated in this study since CarestartTM RDT detects both PfHRP2 and pLDH in 
a single test line. Despite this, our findings show that CarestartTM PfHRP2/pLDH (Pf) 
RDT is still an effective diagnostic tool for malaria surveillance in Kenya.  
 
3.2. P. falciparum histidine-rich proteins 2 and 3 diversity in Kenya 
Diversity of PfHRP2 is currently recognised as a threat to the sensitivity of PfHRP2-
based RDTs, particularly pfhrp2/3 deletion (Gendrot et al., 2018, Gamboa et al., 2010). 
With increasing cases of false negativity being associated with pfhrp2/3 deletion, 
national malaria control programmes and health care providers require information on 
the status of PfHRP2 diversity (Gendrot et al., 2018). This will promote correct 
interpretation of RDT negative results.  
 
In Chapter two, we characterised PfHRP2 diversity of P. falciparum isolates collected 
in western and coastal Kenya from 2007 to 2016. This study demonstrated high 
PfHRP2 diversity in the Kenyan P. falciparum population with 94% of the PfHRP2 
sequences occurring only once as reported elsewhere (Baker et al., 2010, Baker et 
al., 2005). This heterogeneity emanated from differences in the occurrence, number 
and organisation of PfHRP2 amino acids repeat types between isolates. Despite the 
apparent high PfHRP2 diversity, there were noticeable similarities among the P. 
falciparum isolates. These included the complete absence of PfHRP2 repeat types 9 
and 11, the omnipresence of repeat types 2 (AHHAHHAAD) and 7 (AHHAAD) and 
most of the PfHRP2 sequences started and terminated with repeat types 1 and 12, 
respectively. We also identified a semi−conserved PfHRP2 amino acid repeat motif 
comprising repeat types 2, 3, 5, 7, 8, 2 and 7 in 50% of the isolates (Baker et al., 2010). 
A further 27% of the isolates had a motif, comprising repeat types 7, 8, 2 and 7, 
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frequently observed in Malagasy isolates (Mariette et al., 2008). However, a motif 
comprising repeat types 2, 4, 5, 6, 7, and 8 observed in Indian isolates was absent 
among Kenyan isolates (Kumar et al., 2012). 
 
The frequency of thirteen previously identified PfHRP2 repeat types in P. falciparum 
populations from the different study sites in western and coastal Kenya was 
comparable (Baker et al., 2010). Repeats types, 1 to 8, 10 and 12, were highly 
prevalent (>80%) whereas repeat types 13 and 14 were rare (≤8%) akin to isolates 
from other geographical settings (Atroosh et al., 2015, Deme et al., 2014, Bharti et al., 
2017, Li et al., 2015, Wurtz et al., 2013b). In Senegal, however, repeat type 12 is 
uncommon, unlike the present study (Wurtz et al., 2013b). Repeat type 19 was 
observed for the first time in three Kenyan isolates. Besides Kenya, repeat type 19 
has been observed in a few other malaria−endemic countries, namely Senegal, 
Uganda, Mali and the Philippines (Baker et al., 2010, Deme et al., 2014, Bharti et al., 
2017). The similarities between PfHRP2 in our study and studies from other countries 
imply that monoclonal antibodies (mAbs) incorporated in RDTs recognise the same or 
similar PfHRP2 epitopes. This is probably because there is a limited number of 
commercially available PfHRP2−specific mAbs (Lee et al., 2006, Lee et al., 2012). 
Further, it provides a plausible explanation for comparable sensitivity of CarestartTM 
RDT in this study and recent studies (Osanjo et al., 2017, Wanja et al., 2016). 
 
PfHRP2 repeat types 2 and 7 are most likely to influence the sensitivity of RDTs 
targeting PfHRP2. This is because they constitute >50% of total number repeat types 
per isolate and are therefore the most likely contribute to the epitopes involved in 
PfHRP2 detection (Baker et al., 2005). Baker et al. initial findings suggested that the 
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sensitivity of PfHRP2−based RDT is dependent on the number repeat type 2 multiplied 
by the number of repeat type 7 (type 2 × type 7) at parasitemias ≤250 parasites/µl. 
Using a binary logistic regression model (Bakers’ regression model), Baker et al. 
showed that P. falciparum isolates with type 2 × type 7 value below 43 were not 
detectable at this threshold and thus could predict RDT false negativity (Baker et al., 
2005). A study from India and another case study from Senegal supported this finding 
(Wurtz et al., 2013a, Kumar et al., 2012). However, analyses of larger and more 
diverse field samples have revealed that the Bakers’ model cannot exclusively explain 
RDT false negativity (Baker et al., 2010). Low PfHRP2 levels could be an alternative 
explanation (Plucinski et al., 2019).  
 
In this study, the relationship between PfHRP2 levels and PfHRP2 diversity and 
parasite density was also examined. We observed that PfHRP2 levels in blood 
samples from P. falciparum−infected individuals does not correlate with P. falciparum 
parasitemia, type 2 × type 7 values and the total number of PfHRP2 repeats per 
isolate. These findings are not surprising because of existing technical difficulties that 
could impede robust analyses, namely P. falciparum infections are not synchronised 
and PfHRP2 concentration in blood samples reflect that total parasite biomass 
(Dondorp et al., 2005, Tjitra et al., 2001). Furthermore, PfHRP2−specific mAbs 
cross−reactivity with PfHRP3 could also have undermined our analyses, particularly 
at parasite densities >1000 parasites/µl. This phenomenon is hypothesised to be 
driven by similarity between PfHRP2 and PfHRP3. Both protein have amino acid 
repeat types 1, 2, 4 and 7 (Lee et al., 2006, Beshir et al., 2017). 
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Unlike PfHRP2, PfHRP3 was less diverse in the present study in line with previous 
studies (Baker et al., 2005, Wurtz et al., 2013b). This is exemplified by a lower 
proportion of isolates with distinct PfHRP3 repeat type profile and omnipresence of 
previously described repeat types. In addition, PfHRP3 amino acid repeats types were 
organised into two semi−conserved repetitive motifs separated by a single 
non−repetitive region. Isolates from other parts of the world exhibit a similar 
characteristic (Baker et al., 2010, Bharti et al., 2017). There are, however, a few 
isolates from Africa, the Southwest Pacific region and Asia with two non-repetitive 
regions intervening PfHRP3 repetitive regions (Baker et al., 2010, Bharti et al., 2017).  
 
A total of 78 novel repeat types were identified in this study. Of these, 50 and 28 were 
identified in PfHRP2 and PfHRP3, respectively. These repeat types resulted from the 
replacement of at least one amino acid and had low frequencies. This is the first report 
of this phenomenon in sub-Saharan Africa. Similar findings have been reported in the 
Chinese-Myanmar border and India (Bharti et al., 2017, Li et al., 2015). In both 
instances, the novel repeat types arose from the replacement of a single amino acid 
unlike in the present study. Only four out of 78 novel repeat types identified in this 
study have been reported previously (Bharti et al., 2017, Li et al., 2015). These amino 
acid repeat types are THH, AHHAPD, AHHASY and SHHDG. The limited geographic 
distribution and low frequencies of the novel repeat types suggest that they may not 
have a profound impact on the diagnostic performance of RDTs targeting PfHRP2. 
Emergence of the novel repeat types also signals expanding PfHRP2 and PfHRP3 
diversity. 
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Existence of P. falciparum isolates lacking the genes encoding PfHRP2 and PfHRP3 
in natural parasite population represents an emerging challenge for falciparum malaria 
diagnosis. These parasites have been observed in several malaria−endemic countries 
in Africa, Asia, South− and Central−America (Gendrot et al., 2018). None of the P. 
falciparum isolates screened in this study lacked either pfhrp2 or pfhrp3 (PfHRP3 
gene) contrary to a recent report showing pfhrp2 deletion in a few Kenyan isolates 
(Beshir et al., 2017). The study by Beshir et al involved samples collected in 2014, 
seven years after our sample collection, from one of the study sites (Mbita) included 
in the current study. Findings from the current study as well as Beshir et al. suggest 
that pfhrp2 deletion in Kenyan isolates occurred recently. These findings also indicate 
that pfhrp2/3 deletion does not pose an immediate threat to falciparum malaria 
diagnosis by PfHRP2−based RDTs in Kenya. It is important to bear in mind that 
estimation of the prevalence pfhrp2/3 deletion in malaria−endemic settings is 
determined by the proportion of multiple infections (Sepúlveda et al., 2018, Cheng et 
al., 2014). 
 
3.3. Genetic diversity and population structure of P. falciparum in Kenyan-
Ugandan border areas. 
Chapter three estimated the probability of identifying pfhrp2/3 deletion and determined 
of the number of infections per individual, the proportion of multiple polyclonal 
infections, the genetic diversity and population structure of P. falciparum in the 
Kenyan−Ugandan borders areas by genotyping 12 neutral microsatellite (MS) loci 
distributed across the genome of malaria parasites. The number of alleles per MS 
locus indicated the number of infections per individual. This is because P. falciparum 
asexual stages are haploid. Monoclonal infections were defined by the observation of 
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only one allele for all MS loci whereas polyclonal infections were defined by the 
observation of >1 allele in at least one MS locus. Furthermore, the proportion of 
monoclonal infections was used to estimate the probability of identifying isolates 
lacking pfhrp2/3.  
 
The prevalence of multiple infections in the current study was 51%. This indicates that 
the probability of identifying pfhrp2/3 deletion in parasite populations from Kenya was 
49%. It also shows that the prevalence of multiple infections in the study sites 
investigated here was surprisingly lower than reported previously. In 2018, Zhong et 
al. reported that the proportion of polyclonal infections was 75% (Zhong et al., 2018); 
a slight decline from the ≥80% prevalence reported in earlier studies (Bonizzoni et al., 
2009, Zhong et al., 2007, Gatei et al., 2015, Gatei et al., 2010). Since the prevalence 
of multiple infections is a proxy for malaria transmission intensity, our findings suggest 
that transmission has declined in agreement with reduction in malaria parasitemia 
prevalence over the last three decades (Macharia et al., 2018). 
 
We have shown that P. falciparum genetic diversity in Kenya has, however, remained 
unchanged, regardless of changing malaria control strategies, at levels comparable to 
that of parasite populations from other areas in sub−Saharan Africa (Zhong et al., 
2007, Bonizzoni et al., 2009, Ingasia et al., 2016, Gatei et al., 2015, Gatei et al., 2010, 
Anderson et al., 2000, Oyebola et al., 2014). Temporal analyses have demonstrated 
high and stable genetic diversity even after the introduction of artemisinin−based 
combination therapy (ACT) and insecticide−treated nets (ITN) (Gatei et al., 2015, 
Gatei et al., 2010, Chebon et al., 2016). This shows that current malaria interventions 
have not reduced P. falciparum genetic diversity. In fact, P. falciparum diversity 
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increased after ACTs replaced the less efficacious antimalarial drug, 
sulphadoxine−pyrimethamine (SP), in Kenya due to reduced drug selection pressure 
(Chebon et al., 2016). Increasing Anopheles mosquito resistance to pyrethroids and 
large asymptomatic parasite reservoir with higher gametocytaemia are plausible 
explanations for the persistent high P. falciparum genetic diversity (Ototo et al., 2017, 
Zhou et al., 2016, MOH, 2016, Wanjala and Kweka, 2018, Ondeto et al., 2017).  
 
Parasite populations from Nyando and the Kenya−Ugandan border area are panmictic 
as demonstrated by random association of multiple loci in the present study except 
Msambweni were significant non−random association (index of association [𝐼𝑆
𝐴]) was 
observed. Repeated occurrence of four MS haplotypes suggest that P. falciparum 
inbreeding occurs in Msambweni. The level of non−random association observed in 
Msambweni is lower than previously reported in studies from malaria−endemic regions 
including Kenya (Gatei et al., 2015, Gatei et al., 2010, Ingasia et al., 2016, Anderson 
et al., 2000, Zhong et al., 2007). Recent changes in malaria prevalence could have 
altered the frequency of minor alleles and caused non−random association of MS 
alleles in the present study (Snow et al., 2015, Macharia et al., 2018). This hypothesis 
is supported by the observation of significant multilocus linkage disequilibrium (LD) in 
1996 and 2007 after the deployment of insecticide−treated nets (ITNs) in Kenya (Gatei 
et al., 2015, Gatei et al., 2010). Lower malaria prevalence in coastal Kenya than in the 
Lake Victoria region may have also contributed to the significant LD in Msambweni 
and lack thereof in Busia and Nyando (Macharia et al., 2018). It is apparent that 
parasite inbreeding and malaria transmission intensity are inversely related (Anderson 
et al., 2000). 
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Kenyan P. falciparum populations investigated here are connected despite being 
geographically distant (163−1000 Km) as previously described in Africa (Anderson et 
al., 2000). This was shown by low to moderate genetic differentiation and small Nei's 
genetic distance. The parasite populations, Busia vs Msambweni, separated by the 
longest distance (1000 Km) were more genetically close than Busia vs Nyando (163 
Km) and Nyando vs Msambweni (877 Km). This is congruent with the low allele 
frequency variance observed in Busia vs Msambweni (2%) compared to 8% of both 
Busia vs Nyando and Nyando vs Msambweni. Comparable findings have been 
reported in Kenyan P. falciparum populations separated by a similar geographical 
distance as populations from Busia and Msambweni (Ingasia et al., 2016). High 
human−mediated P. falciparum migration accounts for the weak parasite population 
fragmentation in the present and previous studies (Ingasia et al., 2016, Schultz et al., 
2010). This is likely because Busia is an economically important gateway to Uganda, 
a landlocked country, and accounts for most of the human travel between Kenya and 
Uganda. Thus, implying that P. falciparum populations in Kenya have limited gene flow 
barriers. Human−mediated parasite dispersal and gene flow have been reported 
previously in the islands of Lake Victoria and Vanuatu (Lum et al., 2004, Mulenge et 
al., 2016). The existence of large P. falciparum effective population sizes in 
sub−Saharan Africa further explains the weak parasite population fragmentation in our 
study (Anderson et al., 2000). 
 
In conclusion, malaria remains a major public health burden in the tropics where it 
claims a child below five years every two minutes. Current malaria control programmes 
are failing in some regions due to emergence of resistance against antimalaria drugs 
and insecticides as well as P. falciparum lacking gene encoding antigen targeted by 
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malaria RDTs. My dissertation aimed to comparatively evaluate the performance of a 
malaria RDT and describe P. falciparum diversity in Kenya. The findings of the first 
and second publications demonstrate that CareStart™ HRP2/pLDH(Pf) RDT is still an 
effective diagnostic tool for the malaria surveillance program and pfhrp2/3 exon 2 
deletion does not pose an immediate threat to malaria RDT diagnosis in Kenya. They 
also highlight the extensive diversity of both PfHR2 and PfHRP3. The findings of the 
third publication show P. falciparum populations in Kenyan-Ugandan border areas are 
genetic diverse, panmictic and have a weak population structure. These findings 
highlight the fitness of Kenyan P. falciparum populations to withstand malaria control 
interventions. Collectively, this dissertation provides information to promote prompt 
refinement of malaria control and elimination strategies and recommends continued 
surveillance of P. falciparum genetics en route to a malaria−free Kenya. 
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4. SUMMARY 
Malaria is a public health burden in Kenya and P. falciparum contributes largely 
towards malaria related mortality and morbidity. In recent years, rapid diagnostic tests 
(RDT) that target P. falciparum histidine−rich protein 2 (PfHRP2) have been widely 
employed for malaria diagnosis. The circulating P. falciparum isolates lacking both 
pfhrp2 and pfhrp3 threaten the effectiveness of RDT malaria diagnosis based on 
pfhrp2. Against this background, utilizing a Kenyan study cohort, this dissertation (i) 
evaluated malaria diagnosis by RDT (Carestart TM PfHRP2/pLDH (Pf) RDT) against 
microscopy and nucleic acid testing methods; (ii) characterized and interpreted pfhrp2 
and pfhrp3 among circulating parasites; (iii) determined P. falciparum multiple infection 
rate, genetic diversity and population structure in western and coastal Kenya. The 
investigations revealed CareStartTM RDT was comparable with other reliable 
methodologies. This RDT was demonstrated to be an effective tool for malaria 
diagnosis. Among endemic regions, especially in western and coastal Kenya, pfhrp2 
and pfhrp3 omnipresence as well as a high parasite genetic diversity and limited 
population structure were documented. Collectively, these findings will be useful in 
understanding the performance of PfHRP2−based RDTs in Kenya and their 
dependability as tools in malaria control initiatives. 
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5. GERMAN SUMMARY (ZUSAMMENFASSUNG) 
Malaria ist eine Belastung für die öffentliche Gesundheit in Kenia, und P. falciparum 
trägt in hohem Maße zur Sterblichkeit und Morbidität im Zusammenhang mit Malaria 
bei. In den letzten Jahren wurden weit verbreitet Schnelltests  (rapid diagnostic tests 
„RDT“), die das histidinreiche Protein 2 (P. falciparum histidine−rich protein 2; 
PfHRP2) des P. falciparum erkennen, für die Malariadiagnose eingesetzt. Im Umlauf 
befindliche P. falciparum-Stämme, die weder Pfhrp2 noch Pfhrp3 besitzen, bedrohen 
die Malariadiagnose durch RDT. Vor diesem Hintergrund und unter Verwendung einer 
kenianischen Studienkohorte (i) bewertet diese Dissertation die Malariadiagnose 
mittels RDT (Carestart TM PfHRP2/pLDH (Pf) RDT) anhand von Mikroskopie- und 
Nukleinsäuretestmethoden; (ii) charakterisiert und interpretiert sie pfhrp2 und pfhrp3 
der verbreiteten Parasiten; (iii) ermittelt sie  Mehrfachinfektionsraten,  genetische 
Vielfalt und  Populationsstruktur der P. falciparum im Westen und an der Küste Kenias. 
Die Untersuchungen ergaben, dass die RDT mit anderen zuverlässigen Methoden 
vergleichbar sind. RDTs haben sich als wirksames Instrument für die Malariadiagnose 
erwiesen. Parasiten beobachtet wurden. In den endemischen Regionen, 
insbesondere im Westen und an der Küste Kenias, wurde die Allgegenwart der Pfhrp2 
noch Pfhrp3 sowie eine hohe genetische Vielfalt und eine begrenzte 
Populationsstruktur der Parasiten dokumentiert. Zusammengefasst, werden diese 
Ergebnisse hilfreich sein, um die Effektivität von PfHRP2-basierten RDTs in Kenia und 
infolgedessen ihre Zuverlässigkeit als Diagnosemittel bei Initiativen zur 
Malariakontrolle zu verstehen 
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